[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 407
1. Kumarappan CT, Mandal SC: Antitumor activity of polyphenolic extract of Ichnocarpus frutescens. Exp Oncol; 2007 Jun;29(2):94-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Murine Ehrlich ascites carcinoma (EAC) model was used to assess PPE antitumor activity in vivo.
  • RESULTS: Results of in vivo study showed a significant decrease in tumor volume, viable tumor cell count and a significant increase of life span in the PPE treated group compared to untreated one: the life span of PPE treated animals increased by 53.41% (50 mg PPE/kg) and 73.95% (100 mg PPE/kg).
  • CONCLUSION: PPE of Ichnocarpus frutescens possesses strong free radical scavenging activity and anti-tumor activity in vitro and in vivo.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Body Weight / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Cell Count. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Free Radical Scavengers / pharmacology. Humans. Inhibitory Concentration 50. K562 Cells. Leukemia, Erythroblastic, Acute / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Mice. Neoplasm Transplantation. Nitric Oxide / chemistry. Nitric Oxide / metabolism. Plant Leaves / chemistry. Polyphenols. Solvents / chemistry. Superoxides / metabolism. Survival Rate. Toxicity Tests, Acute. Transplantation, Homologous. Tumor Burden / drug effects. U937 Cells. alpha-Tocopherol / pharmacology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704739.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols; 0 / Solvents; 11062-77-4 / Superoxides; 31C4KY9ESH / Nitric Oxide; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


2. Li ZW, Han YL, Liu H, Ding H: [The research of thrombolytic and hemolysis effect from Eupolyphage fibrinolyric protein and its inhibitory effect on S180 ascites tumor of mice]. Zhong Yao Cai; 2010 Jun;33(6):859-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The research of thrombolytic and hemolysis effect from Eupolyphage fibrinolyric protein and its inhibitory effect on S180 ascites tumor of mice].
  • OBJECTIVE: Eupolyphage fibrinolyric protein (EFP) was isolated and purified from Eupolyphage sineses, and its thrombolytic effect, hemolysis effect and inhibitory effect on S180 ascites tumor were investigated.
  • MTT method and Colony-forming method were used to determine the inhibitory effect on S180 ascites tumor.
  • The EFP was also proved the effect of inhibitory on cell proliferation and Colony-forming on S180 ascites tumor of Mice.
  • CONCLUSION: EFP has a strong thrombolytic activity and weak hemolytic, and has inhibitory effect on S180 ascites tumor of mice.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Female. Male. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049605.001).
  • [ISSN] 1001-4454
  • [Journal-full-title] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
  • [ISO-abbreviation] Zhong Yao Cai
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fibrinolytic Agents; 0 / Materia Medica; EC 3.4.21.7 / Fibrinolysin
  •  go-up   go-down


3. Chekulayeva LV, Shevchuk IN, Chekulayev VA, Ilmarinen K: Hydrogen peroxide, superoxide, and hydroxyl radicals are involved in the phototoxic action of hematoporphyrin derivative against tumor cells. J Environ Pathol Toxicol Oncol; 2006;25(1-2):51-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrogen peroxide, superoxide, and hydroxyl radicals are involved in the phototoxic action of hematoporphyrin derivative against tumor cells.
  • Studies were performed on Ehrlich ascites carcinoma (EAC) cells, which were loaded with HPD in phosphate-buffered saline and then irradiated with red light at 630 run in the same buffer.
  • Another interesting finding of our studies is that in tumor cells subjected to HPD-PDT the Fenton-like reactions could play an important role in the generation of OH., and that cell-bound Cu/Zn-superoxide dismutase as well as catalase can protect tumor cells against the phototoxic action of HPD.
  • In addition, we clearly demonstrated the ability of photoexcited HPD to the generation of protein peroxides in tumor cells.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / metabolism. Hematoporphyrin Derivative / pharmacology. Hydrogen Peroxide / metabolism. Hydroxyl Radical / metabolism. Photochemotherapy. Superoxides / metabolism

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566710.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Lipid Peroxides; 0 / Sulfhydryl Compounds; 11062-77-4 / Superoxides; 3352-57-6 / Hydroxyl Radical; 68335-15-9 / Hematoporphyrin Derivative; BBX060AN9V / Hydrogen Peroxide; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione
  •  go-up   go-down


Advertisement
4. Chen T, Li D, Fu YL, Hu W: Screening of QHF formula for effective ingredients from Chinese herbs and its anti-hepatic cell cancer effect in combination with chemotherapy. Chin Med J (Engl); 2008 Feb 20;121(4):363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The QHF formula and the best ratio of ingredients were evaluated in H(22) mouse (KM) models with solid tumors and ascites tumors by uniform design and monitoring inhibition of tumor growth and survival.
  • We then observed the anti-hepatic cell cancer (HCC) effect of QHF when combined with cisplatin (DDP) in H(22) mouse (Balb/c) models with solid tumors and ascites tumors.
  • Evaluating of the therapeutic effect included the general condition of the mice, inhibition of tumor growth, survival, changes in body weight, thymus index, spleen index and WBC counts.
  • Treatment was more efficient in inhibiting the growth of transplanted tumors in H(22) mice when using the QHF formula (55.91%) than using Cinobufotalin (33.25%), Ginsenosides Rg3 (35.11%), PNS (27.12%) or Lentinan (4.97%) separately.
  • QHF also prolonged the life of H(22) ascites hepatic cancer mice more efficiently (38.13%) than Cinobufotalin (25.00%), Ginsenosides Rg3 (27.27%), PNS (23.30%) or Lentinan (24.43%).
  • Combining QHF with DDP the tumor growth inhibition reached 82.54% with a 66.83% increase in survival.
  • QHF combined with DDP can attenuate tumor growth and suppresses the DDP-induced toxic reactions.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304471.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Mukherjee A, Dutta S, Sanyal U: Evaluation of dimethoxydop-NU as a novel anti-tumor agent. J Exp Clin Cancer Res; 2007 Dec;26(4):489-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
  • Dimethoxydop-NU, 1-[2-{3-(2-Chloroethyl)-3-nitrosoureido}ethyl]-3,4-dimethoxy-benzene (Compound 1), was synthesized from 3,4-dimethoxy-phenethylamine as a novel anti-tumor agent based on the structures of the clinical drug CCNU and dopamine, an important endogenous biological amine having anti-angiogenesis property.
  • In vitro screening in two human tumor cell lines, namely promyelocytic leukemia HL-60 and histiocytic lymphoma U-937, revealed its cytotoxicity greater than that of hydroxyurea and comparable to BCNU used as standards.
  • Its in vivo anti-tumoral potency was assessed in the murine ascites tumors Sarcoma-180 (S-180) and Ehrlich ascites carcinoma (EAC) by measuring the increase in median survival times of drug treated (T) over untreated control (C) mice.
  • Results revealed significant tumor regression effects in these tumors.
  • Compound 1 comparable to standards inhibited the synthesis of DNA and RNA in S-180 tumor cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Evaluation, Preclinical. Drug Screening Assays, Antitumor. Humans. Mice. Thymidine / metabolism. Uridine / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365543.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 1-(2-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)-3,4-dimethoxy-benzene; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; VC2W18DGKR / Thymidine; WHI7HQ7H85 / Uridine
  •  go-up   go-down


6. Belakavadi M, Prabhakar BT, Salimath BP: Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells. Biochim Biophys Acta; 2007 Jan;1770(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells.
  • As a model system, we used Ehrlich Ascites Tumor (EAT) cells in which BuA-treatment induces expression of a protein phosphatase enzyme.
  • [MeSH-major] Apoptosis. Butyrates / pharmacology. Carcinoma, Ehrlich Tumor / pathology. Phosphoprotein Phosphatases / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029793.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Butyrates; 3WHH0066W5 / Vanadates; EC 3.1.3.16 / Phosphoprotein Phosphatases
  •  go-up   go-down


7. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH: Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One; 2008;3(10):e3409
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
  • BACKGROUND: Tumor-infiltrating CD8+ T cells are correlated with prolonged progression-free and overall survival in epithelial ovarian cancer (EOC).
  • A significant fraction of EOC patients mount autoantibody responses to various tumor antigens, however the relationship between autoantibodies and tumor-infiltrating T cells has not been investigated in EOC or any other human cancer.
  • METHODOLOGY AND PRINCIPAL FINDINGS: We obtained matched serum and tumor tissue from 35 patients with high-grade serous ovarian cancer.
  • Serum samples were assessed by ELISA for autoantibodies to the common tumor antigen NY-ESO-1.
  • Tumor tissue was examined by immunohistochemistry for expression of NY-ESO-1, various T cell markers (CD3, CD4, CD8, CD25, FoxP3, TIA-1 and Granzyme B) and other immunological markers (CD20, MHC class I and MHC class II).
  • Lymphocytic infiltrates varied widely among tumors and included cells positive for CD3, CD8, TIA-1, CD25, FoxP3 and CD4.
  • Twenty-six percent (9/35) of patients demonstrated serum IgG autoantibodies to NY-ESO-1, which were positively correlated with expression of NY-ESO-1 antigen by tumor cells (r = 0.57, p = 0.0004).
  • Autoantibodies to NY-ESO-1 were associated with increased tumor-infiltrating CD8+, CD4+ and FoxP3+ cells.
  • In an individual HLA-A2+ patient with autoantibodies to NY-ESO-1, CD8+ T cells isolated from solid tumor and ascites were reactive to NY-ESO-1 by IFN-gamma ELISPOT and MHC class I pentamer staining.
  • CONCLUSION AND SIGNIFICANCE: We demonstrate that tumor-specific autoantibodies and tumor-infiltrating T cells are correlated in human cancer and can be directed against the same target antigen.
  • This implies that autoantibodies may collaborate with tumor-infiltrating T cells to influence clinical outcomes in EOC.
  • [MeSH-major] Antigens, Neoplasm / immunology. Autoantibodies / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Membrane Proteins / immunology. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):218-21 [8314142.001]
  • [Cites] J Immunol. 1994 Mar 1;152(5):2393-400 [8133050.001]
  • [Cites] J Immunol. 1994 May 15;152(10):4993-9 [7909829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6 [7831305.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210 [7834119.001]
  • [Cites] Surg Oncol. 1995 Feb;4(1):41-9 [7780612.001]
  • [Cites] Hum Gene Ther. 1996 Jul 10;7(11):1351-65 [8818723.001]
  • [Cites] Cancer Treat Res. 1996;82:115-46 [8849947.001]
  • [Cites] Cell Immunol. 1996 Dec 15;174(2):116-28 [8954611.001]
  • [Cites] Cell Immunol. 1997 Feb 1;175(2):150-6 [9023420.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1723-34 [9137096.001]
  • [Cites] Nat Med. 1998 May;4(5):627-30 [9585241.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):501-7 [9816009.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):743-50 [9869522.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):76-81 [9889034.001]
  • [Cites] Anticancer Drugs. 1999 Feb;10(2):219-27 [10211553.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):875-8 [10216509.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):86-92 [10385556.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1598-605 [15547530.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):590-6 [15699022.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1153-8 [15870936.001]
  • [Cites] Crit Rev Immunol. 2005;25(2):75-102 [15952931.001]
  • [Cites] Am J Reprod Immunol. 2005 Aug;54(2):55-62 [16105096.001]
  • [Cites] Cell Immunol. 2005 Apr;234(2):81-101 [16038891.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8326-31 [16322292.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 19;81(8):602-11 [2495368.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6302-10 [2205379.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1618-29 [2213099.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):458-61 [2227561.001]
  • [Cites] J Immunol. 1991 Mar 1;146(5):1700-7 [1704404.001]
  • [Cites] Cancer Res. 1991 Apr 1;51(7):1934-9 [2004379.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4257-65 [1868446.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8681-5 [1326761.001]
  • [Cites] Cancer Immunol Immunother. 1993;36(3):191-7 [8439980.001]
  • [Cites] Surgery. 1993 Aug;114(2):227-34 [8342128.001]
  • [Cites] J Immunol. 1993 Nov 15;151(10):5472-80 [8228239.001]
  • [Cites] J Immunol. 1993 Nov 15;151(10):5481-91 [8228240.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:212-20 [16343233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):762-8 [16391298.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Autoimmun Rev. 2006 Jul;5(6):424-8 [16890898.001]
  • [Cites] Cancer J Sci Am. 1996 Sep-Oct;2(5):263-72 [9166543.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):21-3 [17183612.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6A):4015-8 [17195451.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):762-72 [17308072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):301-8 [17433871.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):606-14 [17415711.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3591-6 [17575223.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):75-81 [17433425.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4139-45 [17634541.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8378-87 [17804754.001]
  • [Cites] Dis Markers. 2007;23(5-6):445-52 [18057527.001]
  • [Cites] Nat Med. 2008 Jan;14(1):28-36 [18157142.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):415-20 [18037158.001]
  • [Cites] Immunol Rev. 2008 Apr;222:101-16 [18363996.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2413-20 [18413832.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):215-9 [18314181.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4214-23 [10632363.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2268-78 [10873077.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Immunol Immunother. 2000 Jul;49(4-5):181-5 [10941900.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 7):47-9 [10952127.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Jan;94(1):114-20 [11134836.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3025-30 [11595690.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):21-7 [12085250.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406 [12237285.001]
  • [Cites] APMIS. 2002 Aug;110(7-8):545-53 [12390412.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6076-83 [14522938.001]
  • [Cites] Int Immunopharmacol. 2003 Dec;3(13-14):1699-714 [14636822.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6453-60 [14695148.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):64-75 [14764031.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3401-9 [15161695.001]
  • [Cites] Int J Clin Oncol. 2004 Feb;9(1):42-6 [15162825.001]
  • [Cites] Pathol Oncol Res. 2004;10(2):80-4 [15188023.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):190-6 [8261438.001]
  • (PMID = 18923710.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / CTAG1B protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2561074
  •  go-up   go-down


8. Chandrashekar NS, Hiremath SR: Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. Recent Pat Anticancer Drug Discov; 2007 Nov;2(3):235-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study.
  • The purpose of this study was to determine the permeation of the hydrophilic compound 5-fluorouracil through human epidermal membranes, Ehrlich Ascites Carcinoma (EAC) cells were used as a model cell line to evaluate the cytotoxic concentration and anti-tumor activity of 5-fluorouracil (5-FU) through transdermal drug delivery for tumors.
  • For 5-fluorouracil monolithic matrix transdermal patch, the results were statistically significant (p<0.05) compared to untreated control, anti-tumor activity was very effective compared to intravenous therapy.
  • Recent patents has been reported for suitable treatment of tumors and cancer, by topical and transdermal applications.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use
  • [MeSH-minor] Adhesiveness. Administration, Cutaneous. Animals. Cell Line, Tumor. Chemistry, Physical. Drug Delivery Systems. Humans. Irritants / toxicity. Mice. Mice, Inbred BALB C. Physicochemical Phenomena. Rabbits. Survival Analysis

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221066.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Irritants; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Lambert IH, Klausen TK, Bergdahl A, Hougaard C, Hoffmann EK: ROS activate KCl cotransport in nonadherent Ehrlich ascites cells but K+ and Cl- channels in adherent Ehrlich Lettré and NIH3T3 cells. Am J Physiol Cell Physiol; 2009 Jul;297(1):C198-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ROS activate KCl cotransport in nonadherent Ehrlich ascites cells but K+ and Cl- channels in adherent Ehrlich Lettré and NIH3T3 cells.
  • Addition of H(2)O(2) (0.5 mM) to Ehrlich ascites tumor cells under isotonic conditions results in a substantial (22 +/- 1%) reduction in cell volume within 25 min.
  • It is suggested that H(2)O(2) activates electroneutral KCl cotransport in Ehrlich ascites tumor cells and not K(+) and Cl(-) channels.
  • The effect of H(2)O(2) on cell volume was blocked by the serine-threonine phosphatase inhibitor calyculin A, indicating an important role of serine-threonine phosphorylation in the H(2)O(2)-mediated activation of KCl cotransport in Ehrlich cells.
  • In contrast, addition of H(2)O(2) to adherent cells, e.g., Ehrlich Lettré ascites cells, a subtype of the Ehrlich ascites tumor cells, and NIH3T3 mouse fibroblasts increased the K(+) and Cl(-) conductances after hypotonic cell swelling.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / metabolism. Cell Adhesion. Chloride Channels / metabolism. Fibroblasts / metabolism. Oxidative Stress. Potassium Channels / metabolism. Reactive Oxygen Species / metabolism. Symporters / metabolism
  • [MeSH-minor] Animals. Carboxylic Acids / pharmacology. Cell Line, Tumor. Cell Size. Enzyme Inhibitors / pharmacology. Female. Hydrogen Peroxide / metabolism. Hypotonic Solutions. Indenes / pharmacology. Ion Transport. Mice. NIH 3T3 Cells. Nitrates / metabolism. Osmotic Pressure. Oxazoles / pharmacology. Phosphoprotein Phosphatases / metabolism. Phosphorylation. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419998.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ((dihydroindenyl)oxy)alkanoic acid; 0 / Carboxylic Acids; 0 / Chloride Channels; 0 / Enzyme Inhibitors; 0 / Hypotonic Solutions; 0 / Indenes; 0 / Nitrates; 0 / Oxazoles; 0 / Potassium Channels; 0 / Reactive Oxygen Species; 0 / Symporters; 0 / potassium-chloride symporters; 101932-71-2 / calyculin A; BBX060AN9V / Hydrogen Peroxide; EC 3.1.3.16 / Phosphoprotein Phosphatases
  •  go-up   go-down


10. Akev N, Turkay G, Can A, Gurel A, Yildiz F, Yardibi H, Ekiz EE, Uzun H: Effect of Aloe vera leaf pulp extract on Ehrlich ascites tumours in mice. Eur J Cancer Prev; 2007 Apr;16(2):151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aloe vera leaf pulp extract on Ehrlich ascites tumours in mice.
  • ) Burm. fil., a few recent studies have shown that preparations of the plant leaves can prevent or regress the growth of certain tumours.
  • In this study, undertaken with A. vera leaf pulp extract against Ehrlich ascites tumours in mice, the animals were separated into five groups: I - healthy control, II - tumour control, III - experiment 1 (extract given before tumour inoculation), IV - experiment 2 (extract given with tumour inoculation) and V - experiment 3 (extract given after tumour inoculation).
  • Ehrlich ascites tumours (0.33 ml) were injected subcutaneously into groups II-V.
  • Tumour size, thymus and spleen weights were measured, as well as leucocyte count, tumour necrosis factor-alpha and sialic acid as tumour markers.
  • The best inhibitory effect on tumour growth was obtained with the extract given prophylactically before tumour implantation (experiment 1), although Aloe extract also regressed tumour sizes when given simultaneously with (experiment 2), or therapeutically after (experiment 3), tumour implantation.
  • Accordingly, serum sialic acid and tumour necrosis factor-alpha levels, chosen as tumour markers, which were raised in the tumour control group, were significantly decreased by the prophylactic administration of the extract.
  • The increase in leucocyte count seen in experiment 1 and 2 groups, along with lymphoid hyperplasia observed in spleen and thymus necroscopy, lead us to think that the tumour preventive effect of Aloe could be due to its immunomodulatory activity.
  • [MeSH-major] Aloe. Carcinoma, Ehrlich Tumor / drug therapy. Phytotherapy. Plant Extracts / therapeutic use. Plant Leaves

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17297391.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


11. Pal S, Sadhu AS, Patra S, Mukherjea KK: Histological vis-a-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models. J Exp Clin Cancer Res; 2008;27:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The animals were randomly divided into four sets--Set I: Erhlich Ascites Carcinoma (EAC) challenged mice; Set II: Normal mice; Set III: Drug treated mice, Set IVA Cisplatin (CDDP) treated mice, Set IV B EAC challenged Cisplatin treated mice.
  • For Set I only tumor cell count and packed cell volume (PCV) of tumor cells were recorded.
  • Set IV B was studied for tumor cell count after treatment with CDDP for 10 days.
  • [MeSH-major] Adenosine Triphosphate / analogs & derivatives. Antineoplastic Agents / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Organoplatinum Compounds / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2001 Sep 4;486(4):217-47 [11516927.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):217-23 [6153149.001]
  • [Cites] Cancer Treat Rep. 1987 May;71(5):485-8 [3567974.001]
  • [Cites] Chemotherapy. 1987;33(4):278-86 [3608628.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1281-9 [3040920.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):913-8 [2827883.001]
  • [Cites] J Inorg Biochem. 1991 Mar;41(4):293-8 [2056310.001]
  • [Cites] Invest New Drugs. 1995;13(1):23-32 [7499104.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Sep;16(3):255-60 [9387898.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):215-26 [16723633.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8800-9 [17875721.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9077-83 [17909011.001]
  • (PMID = 19014472.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / platinum dichloride-adenosine triphosphate complex; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ PMC2661047
  •  go-up   go-down


12. Sadzuka Y, Sugiyama I, Tsuruda T, Sonobe T: Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin. Int J Pharm; 2006 Apr 7;312(1-2):83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The uptake of DOX into Ehrlich ascites carcinoma cells by the liposomes covered with PEG-CHO was higher than the other liposomes.
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor. Cell Line, Tumor. Chemistry, Pharmaceutical. Leukemia P388. Liposomes. Molecular Weight. Particle Size. Surface Properties

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457972.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


13. Digkas EN, Chrisafi S, Passadaki T, Tsalkidis A, Hatzimichail A, Vargemezis V, Lialiaris TS: In vitro and in vivo cytogenetic effects of recombinant human erythropoietin on the frequency of sister chromatid exchanges alone or in combination with mitomycin C. Chemotherapy; 2010;56(3):239-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to study the action of EPO on DNA of two cell types, human lymphocytes in vitro and on P388 ascites tumor cells inoculated in BDF1 mice in the presence and absence of the genotoxic agent mitomycin C (MMC).

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20551641.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Valentin L, Ameye L, Testa A, Lécuru F, Bernard JP, Paladini D, Van Huffel S, Timmerman D: Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol; 2006 Jul;102(1):41-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe ultrasound characteristics of adnexal malignancies, i.e., borderline ovarian tumors, primary invasive ovarian epithelial cancer stage 1, primary invasive ovarian epithelial cancer stages 2-4, rare types of malignancy, and metastatic tumors.
  • RESULTS: Of 1,066 masses, 266 were malignant and are included: 55 ovarian borderline tumors, 144 primary invasive epithelial ovarian cancers (42 stage 1, 102 stages 2-4), 25 rare malignancies, and 42 metastatic tumors.
  • Most (56%) metastatic tumors and most (60%) rare types of tumor were solid and richly vascularized at color Doppler ultrasound examination (on a scale ranging from 1 to 4, color score based on subjective evaluation was 3 or 4 in 88% and 86%, respectively).
  • Borderline ovarian tumors and stage 1 primary invasive ovarian epithelial cancers differed from stages 2-4 primary invasive ovarian epithelial cancers: they were larger (median volume 375 ml and 695 ml vs. 209 ml; P = 0.0213 and 0.0001), a larger proportion contained papillary projections (64% and 67% vs. 41%; P = 0.0072 and 0.0054), they were more often multilocular cysts without solid components (18% and 14% vs. 2%; P < 0.0017 and 0.0204), but they were less often purely solid (5% and 7% vs. 38%; P <or= 0.0001 and 0.0005).
  • With increasing degree of invasiveness - from borderline epithelial ovarian tumors via stage 1 invasive epithelial ovarian tumors to stages 2-4 invasive epithelial ovarian tumors - ascites became more common (9% vs. 31% vs. 61%; P = 0.0082, <0.0001, and 0.0017), and, among tumors with solid components (n = 179), the proportion of tumor consisting of solid tissue increased (median 2%-10%-34%; P = 0.0212, <0.0001, and 0.0003).
  • CONCLUSION: Papillary projections are characteristic of borderline tumors and stage 1 primary invasive epithelial ovarian cancer.
  • A small proportion of solid tissue at ultrasound examination makes a malignant mass more likely to be a borderline tumor or a stage 1 epithelial ovarian cancer than an advanced ovarian cancer, a metastasis, or a rare type of tumor.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386783.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Jagetia GC, Venkatesha VA: Enhancement of radiation effect by Aphanamixis polystachya in mice transplanted with Ehrlich ascites carcinoma. Biol Pharm Bull; 2005 Jan;28(1):69-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of radiation effect by Aphanamixis polystachya in mice transplanted with Ehrlich ascites carcinoma.
  • The effect of radiation on tumor tissue can be optimized by adding radiosensitizing agents, in order to achieve a greater degree of tumor damage than expected from the use of either treatment alone.
  • The ethanolic extract of Aphanamixis polystachya (APE) was tested in Swiss albino mice transplanted with Ehrlich ascites carcinoma (EAC) and exposed to various doses of gamma-radiation.
  • The splitting of 50 mg into two equal fractions of 25 mg and administering the split dose with a gap of 8 h on 1, 3, 5, 7 or 9 d of tumor inoculation resulted in an increased survival even when the drug was administered at late stages (day 5) of tumor development.
  • Treatment of tumor bearing mice with APE before irradiation further reduced the activities of various antioxidant enzymes like glutathione peroxidase, glutathione-s-transferase, superoxide dismutase and catalase at different post last drug administration (PLDA) times.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / radiotherapy. Gamma Rays / therapeutic use. Meliaceae. Radiation-Sensitizing Agents / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635166.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Radiation-Sensitizing Agents
  •  go-up   go-down


16. Lialiaris TS, Papachristou F, Mourelatos C, Simopoulou M: Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. Anticancer Drugs; 2009 Sep;20(8):746-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo.
  • The inhibitory effect of phenothiazines in tumor growth and cancer cell proliferation in vitro and in vivo has been established.
  • In-vitro studies were performed on human lymphocyte cultures and in-vivo studies involved Ehrilch ascites tumor (EAT) cells.
  • The combination of chlorpromazine plus mitomycin C exerted cytostatic and cytotoxic actions in EAT cells, significantly increased the survival span of the mice inoculated with EAT cells, and suppressed the expected tumor growth increase.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Chlorpromazine / pharmacology. Chlorpromazine / therapeutic use. Lymphocytes / drug effects. Sister Chromatid Exchange / drug effects

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. Chlorpromazine .
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584706.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3G6A5W338E / Caffeine; 50SG953SK6 / Mitomycin; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


17. Asada R, Kageyama K, Tanaka H, Matsui H, Kimura M, Saitoh Y, Miwa N: Antitumor effects of nano-bubble hydrogen-dissolved water are enhanced by coexistent platinum colloid and the combined hyperthermia with apoptosis-like cell death. Oncol Rep; 2010 Dec;24(6):1463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to erase reactive oxygen species (ROS) related with the proliferation of tumor cells by reducing activity of hydrogen, we developed functional water containing nano-bubbles (diameters: <900 nm for 71%/population) hydrogen of 1.1-1.5 ppm (the theoretical maximum: 1.6 ppm) with a reducing ability (an oxidation-reduction potential -650 mV, normal water: +100-200 mV) using a microporous-filter hydrogen-jetting device.
  • We showed that hydrogen water erased ROS indispensable for tumor cell growth by ESR/spin trap, the redox indicator CDCFH-DA assay, and was cytotoxic to Ehrlich ascites tumor cells as assessed by WST-8 assay, crystal violet dye stain and scanning electron microscopy, after 24-h or 48-h incubation sequent to warming at 37°C or 42°C.
  • Thus, the nano-bubble hydrogen water with platinum colloid is potent as an anti-tumor agent.

  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. PLATINUM .
  • Hazardous Substances Data Bank. Water .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042740.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Colloids; 0 / Gases; 059QF0KO0R / Water; 49DFR088MY / Platinum; 7YNJ3PO35Z / Hydrogen
  •  go-up   go-down


18. Nersesian AK, Muradian RE, Arsenian FG: [Micronuclear and antitumor activities of two newly synthesized pyrimidine derivatives]. Tsitologiia; 2008;50(1):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been shown that both compounds are slightly toxic and have no antitumor activity in mice with Ehrlich's ascites carcinoma.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Pyrazoles / therapeutic use. Pyrazoles / toxicity. Pyrimidines / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409373.001).
  • [ISSN] 0041-3771
  • [Journal-full-title] Tsitologiia
  • [ISO-abbreviation] Tsitologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Pyrazoles; 0 / Pyrimidines; 8N3DW7272P / Cyclophosphamide; K8CXK5Q32L / pyrimidine
  •  go-up   go-down


19. Salgado FL, Lopes Filho GJ, de Moura LA: Effect of experimental ehrlich ascites tumors on healing of abdominal wall wounds in mice. Wounds; 2009 Oct;21(10):262-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of experimental ehrlich ascites tumors on healing of abdominal wall wounds in mice.
  • The present study aimed to analyze histological modifications induced by the presence of Ehrlich ascites tumors on laparotomic surgical scars in BALB/c mice.
  • Half of the mice were injected with Ehrlich tumor cells, and 7 days later (day 7) all mice underwent laparotomy.
  • On day 11, the scar was resected in 10 mice with the tumor and in the 10 control mice.
  • Mice injected with tumor cells gained weight due to ascites growth.
  • Histologic results showed that Ehrlich ascites tumor cells did not affect initial acute inflammation, re-epithelization, and formation of granulation tissue (P = ns).
  • Chronic inflammation and fibroblast proliferation were, however, significantly decreased in mice with tumors, whereas collagenization had increased (P = 0.001).
  • These results show that Ehrlich ascites tumors affect the healing process in mice.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25902710.001).
  • [ISSN] 1044-7946
  • [Journal-full-title] Wounds : a compendium of clinical research and practice
  • [ISO-abbreviation] Wounds
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Xu S, Kojima-Yuasa A, Azuma H, Kennedy DO, Konishi Y, Matsui-Yuasa I: Comparison of glutathione reductase activity and the intracellular glutathione reducing effects of 13 derivatives of 1'-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem Biol Interact; 2010 May 14;185(3):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of glutathione reductase activity and the intracellular glutathione reducing effects of 13 derivatives of 1'-acetoxychavicol acetate in Ehrlich ascites tumor cells.
  • In the current study, we investigated the inhibitory activities of 13 derivatives of (S)-ACA on tumor cell viability, intracellular GSH level and GR activity.
  • Correlations were found among a decrease in cell viability, intracellular GSH levels and the activity of GR in Ehrlich ascites tumor cells treated with the various ACA analogues.
  • [MeSH-major] Benzyl Alcohols / chemistry. Benzyl Alcohols / pharmacology. Carcinoma, Ehrlich Tumor / metabolism. Glutathione / metabolism. Glutathione Reductase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20230805.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzyl Alcohols; 52946-22-2 / 1'-acetoxychavicol acetate; EC 1.8.1.7 / Glutathione Reductase; GAN16C9B8O / Glutathione
  •  go-up   go-down


21. D'Souza SS, Gururaj AE, Raj HM, Rössler J, Salimath BP: Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1. J Gene Med; 2010 Dec;12(12):968-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1.
  • BACKGROUND: Inhibition of tumor angiogenesis is a promising approach for cancer therapy and the Tie-2/angiopoietin pathway appears to play an important role.
  • METHODS: Ehrlich ascites tumor (EAT) cells were stably transfected to overexpress a truncated form of sTie-2.
  • Furthermore, recombinant sTie-2 produced by the baculovirus expression system was used to sequester angiopoietins in the murine ascites carcinoma model.
  • The effect of sTie-2 treatment alone or in combination with sFLT-1 on the weight of the animal, ascites cell number and volume was studied.
  • However, sTie-2 transfected EAT cells transplanted into nude mice reduced tumor burden and demonstrated a reduction in ascites formation and peritoneal angiogenesis.
  • Recombinant sTie-2 showed angiogenic activity in the tube formation and wound healing assay in vitro. sTie-2 treatment alone or in combination with sFLT-1 in an ascites tumor mouse model resulted in reduced peritoneal angiogenesis, with a concomitant decrease in tumor cell number, volume of ascites and the number of invasive tumor cells, as assayed by CD31 staining.
  • CONCLUSIONS: The findings of the present study demonstrate an important role for the Tie-2/angiopoietin pathway in the formation of tumor vasculature and suggest that sTie-2 might yield useful anticancer therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ehrlich Tumor / pathology. Carcinoma, Ehrlich Tumor / therapy. Neovascularization, Pathologic / prevention & control. Receptor, TIE-2 / therapeutic use. Vascular Endothelial Growth Factor Receptor-1 / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 21104971.001).
  • [ISSN] 1521-2254
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietin-2; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Receptor, TIE-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


22. Arimura T, Kojima-Yuasa A, Tatsumi Y, Kennedy DO, Matsui-Yuasa I: Involvement of polyamines in evening primrose extract-induced apoptosis in Ehrlich ascites tumor cells. Amino Acids; 2005 Feb;28(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of polyamines in evening primrose extract-induced apoptosis in Ehrlich ascites tumor cells.
  • We previously demonstrated that evening primrose extract (EPE) induced apoptosis and inhibited the DNA synthesis in Ehrlich ascites tumor cells (EATC) and suggested that EPE-induced inhibition of the growth of EATC are via at least two pathway differentially modulated by reactive oxygen species, notably intracellular peroxides.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Ehrlich Tumor / pathology. Oenothera biennis / chemistry. Plant Extracts / pharmacology. Polyamines / pharmacology
  • [MeSH-minor] Animals. Cell Survival / drug effects. Chromatography, High Pressure Liquid / methods. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / drug effects. Dose-Response Relationship, Drug. Putrescine / pharmacology. Spermidine / pharmacology. Spermine / pharmacology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. Putrescine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700107.001).
  • [ISSN] 0939-4451
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Plant Extracts; 0 / Polyamines; 2FZ7Y3VOQX / Spermine; U87FK77H25 / Spermidine; V10TVZ52E4 / Putrescine
  •  go-up   go-down


23. Malghe YS, Prabhu RC, Raut RW: Synthesis, characterization and biological activities of mixed ligand Zr(IV) complexes. Acta Pol Pharm; 2009 Jan-Feb;66(1):45-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The complexes were also screened for cytotoxicity studies against Ehrlich ascites cells and Daltons lymphoma ascites cells and show very low cytotoxicity.
  • [MeSH-minor] Amino Acids / chemistry. Amphotericin B / pharmacology. Animals. Carcinoma, Ehrlich Tumor. Cell Line, Tumor. Ligands. Oxyquinoline / chemistry. Vancomycin / pharmacology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. 8-HYDROXYQUINOLINE .
  • Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19226968.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Ligands; 5UTX5635HP / Oxyquinoline; 6Q205EH1VU / Vancomycin; 7XU7A7DROE / Amphotericin B; C6V6S92N3C / Zirconium
  •  go-up   go-down


24. Kwiecień I, Sokołowska M, Włodek L: Nephroprotective effect of cystathionine is due to its diverse action on the kidney and Ehrlich ascites tumor cells. Pharmacol Rep; 2007 Sep-Oct;59(5):553-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroprotective effect of cystathionine is due to its diverse action on the kidney and Ehrlich ascites tumor cells.
  • Tumor cells, unlike normal cells, are characterized by trace cystathionase (CST) activity and sulfane sulfur levels.
  • The present studies aimed to established whether cystathionine (CT), a substrate of cystathionase, can selectively influence the thiol-dependent antioxidant power of the kidney and Ehrlich ascites tumor (EAT).
  • CT treatment reversed the changes in renal concentrations of non-protein thiols (NPSH), reactive oxygen species (ROS), sulfane sulfur and activities of rhodanese, cystathionase and glutathione S-transferase (GST) in tumor-bearing mice, which returned to the level observed in healthy animals.
  • It indicates that CT can selectively protect the kidney of tumor-bearing mice against nephrotoxicity of drugs as well as restore biological function of sulfane sulfur.
  • On the other hand, cisplatin (CP) did not affect any of the parameters under study in the kidney of tumor-bearing mice.
  • Interestingly, cisplatin markedly lowered glutathione S-transferase activity and increased sulfane sulfur level and rhodanese activity in tumor cells.
  • It is also worth noting that CP doses devoid of nephrotoxic effect in tumor-bearing mice could enhance cystathionine action on the kidney, causing an additional increase in NPSH and CST and rhodanese activity.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Ehrlich Tumor / metabolism. Cisplatin / adverse effects. Cystathionine / pharmacology. Kidney / drug effects. Protective Agents / pharmacology
  • [MeSH-minor] Anaerobiosis. Animals. Antioxidants / metabolism. Cystathionine gamma-Lyase / metabolism. Cysteine / metabolism. Female. Glutathione Transferase / metabolism. Mice. Reactive Oxygen Species / metabolism. Sulfhydryl Compounds / metabolism. Thiosulfate Sulfurtransferase / metabolism. Tumor Cells, Cultured. gamma-Glutamyltransferase / metabolism

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048956.001).
  • [ISSN] 1734-1140
  • [Journal-full-title] Pharmacological reports : PR
  • [ISO-abbreviation] Pharmacol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Protective Agents; 0 / Reactive Oxygen Species; 0 / Sulfhydryl Compounds; 375YFJ481O / Cystathionine; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.5.1.18 / Glutathione Transferase; EC 2.8.1.1 / Thiosulfate Sulfurtransferase; EC 4.4.1.1 / Cystathionine gamma-Lyase; K848JZ4886 / Cysteine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Majumder S, Dutta P, Mookerjee A, Choudhuri SK: The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chem Biol Interact; 2006 Feb 1;159(2):90-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
  • The present study describes the resistance reversal potentiality of novel copper complex, viz., copper N-(2-hydroxy acetophenone) glycinate (CuNG) developed by us in Dox-resistant Ehrlich ascites carcinoma (EAC/Dox) cells.
  • In vivo studies with male Swiss albino mice bearing ascitic growth of EAC/Dox showed tremendous increase in life span (treated/control, T/C = 453%) for the treated group with apparent regression of tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Copper / pharmacology. Doxorubicin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289015.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 789U1901C5 / Copper; 80168379AG / Doxorubicin; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; GAN16C9B8O / Glutathione
  •  go-up   go-down


26. Wu FY, Huang GS, Jiang JW, Wang F, Xu XD, Peng DY: [Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances 5-FU sensitivity]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Feb;30(2):304-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances 5-FU sensitivity].
  • OBJECTIVE: To investigate the inhibitory effect of survivin antisense oligodeoxynuleotides (ASODN) mediated by polyethylenimine (PEI) on hepatocelluar carcinoma SMMC-7721 cell proliferation and its effect on chemosensitivity to 5-FU in tumor-bearing mice.
  • In mouse models of transplanted H22 cell hepatocarcinoma and ascites tumor, the effect of 5-FU combined with PEI-ASODN on the weight and volume of the subcutaneous tumors was examined.
  • The tumor inhibition rate in the tumor-bearing mice was calculated and the average survival time recorded.
  • In the tumor-bearing mice, the tumor weight and volume were obviously reduced with a tumor inhibition rate of 56.91% and volume inhibition rate of 57.83%, significantly different from those in saline-treated mice (P<0.01).
  • In the mice bearing ascites tumor, the average survival time was 22.0 days in saline group and 42.7 days in 5-FU+PEI-ASODN treatment group, showing a a life-prolonging rate of 94.09% in the latter group.
  • CONCLUSION: PEI-ASODN complex can significantly inhibit the proliferation of hepatocarcinoma SMMC-7721 cells and enhance 5-FU chemosensitivity of the tumor cells in vitro and transplanted H22 tumors in mice.
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Synergism. Female. Male. Mice

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20159707.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Birc5 protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Repressor Proteins; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Majumder S, Chatterjee S, Pal S, Biswas J, Efferth T, Choudhuri SK: The role of copper in drug-resistant murine and human tumors. Biometals; 2009 Apr;22(2):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of copper in drug-resistant murine and human tumors.
  • In the present investigation, we addressed the question whether metal copper might be involved in drug resistance of murine and human tumors.
  • We found that the blood serum of tumor-bearing mice contained higher amounts of copper than healthy mice with tumors.
  • Secondly, mice bearing doxorubicin-resistant Ehrlich ascites carcinoma- or cyclophosphamide-resistant Lewis lung carcinoma contained more copper in their serum than mice bearing the corresponding drug-sensitive parental tumors.
  • Furthermore, the analysis of patients with breast cancer, colon carcinoma or lung cancer showed that the serum copper contents were higher in patients not responding to chemotherapy when compared to patients whose tumors responded to treatment.
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Drug Resistance, Multiple. Female. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956143.001).
  • [ISSN] 1572-8773
  • [Journal-full-title] Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
  • [ISO-abbreviation] Biometals
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 789U1901C5 / Copper
  •  go-up   go-down


28. Fariña LA, Martínez MC: [Chylous ascites following radical nephrectomy. Conservative management whithout paracentesis]. Actas Urol Esp; 2009 Jun;33(6):703-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chylous ascites following radical nephrectomy. Conservative management whithout paracentesis].
  • [Transliterated title] Ascitis quilosa después de nefrectomía radical laparoscópica. Tratamiento conservador sin paracentesis.
  • INTRODUCTION: Chylous ascites is a rare complication after a number of abdominal and retroperitoneal surgeries.
  • PATIENT AND METHOD: A 60 year-old woman was treated with a laparoscopic radical nephrectomy for a 9.5x7.5 cm, pT2 pN0 tumor.
  • After six months of follow-up, no simptoms nor CT- signs of ascites or tumor recurred.
  • COMMENT: A conservative treatment, with diuretics, low lipids and salt diet, and eventually repeated paracentesis should be the first options for chylous ascites after nephrectomy.
  • In the last years, several laparoscopic techniques had been described to treat chylous ascites in a low invasive way, but the intrinsic difficulties of such a re-operation much be considered.
  • [MeSH-major] Chylous Ascites / etiology. Chylous Ascites / therapy. Nephrectomy / adverse effects

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711757.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Sakai M, Fonseca ES, Oloris SC, Matsuzaki P, Otake AH, Leite KR, Massoco CO, Dagli ML, Palermo-Neto J: Effects of peripheral-type benzodiazepine receptor ligands on Ehrlich tumor cell proliferation. Eur J Pharmacol; 2006 Nov 21;550(1-3):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of peripheral-type benzodiazepine receptor ligands on Ehrlich tumor cell proliferation.
  • Peripheral-type benzodiazepine receptor expression has been associated with tumor malignity, and its subcellular localization is important to define its function in tumor cells.
  • We investigated the presence of peripheral-type benzodiazepine receptors in Ehrlich tumor cells, and the in vitro effects of peripheral-type benzodiazepine receptors ligands on tumor cell proliferation.
  • Our results demonstrate the presence of peripheral-type benzodiazepine receptor in the nucleus of Ehrlich tumor cells (85.53+/-12.60%).
  • They also show that diazepam and Ro5-4864 (peripheral-type benzodiazepine receptor agonists) but not clonazepam (a molecule with low affinity for the peripheral-type benzodiazepine receptor) decreased the percentage of tumor cells in G0-G1 phases and increased that of cells in S-G2-M phases.
  • Altogether, these data suggest that the presence of peripheral-type benzodiazepine receptor within the nucleus of Ehrlich tumor cells is associated with tumor malignity and proliferation capacity.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / pathology. Receptors, GABA-A / drug effects

  • Hazardous Substances Data Bank. 4-CHLORODIAZEPAM .
  • Hazardous Substances Data Bank. CLONAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027961.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzodiazepinones; 0 / GABA Modulators; 0 / Isoquinolines; 0 / Ligands; 0 / Receptors, GABA-A; 14439-61-3 / 4'-chlorodiazepam; 5PE9FDE8GB / Clonazepam; 85340-56-3 / PK 11195
  •  go-up   go-down


30. Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, Jensen PB: Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res; 2005 Sep 15;11(18):6722-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
  • EXPERIMENTAL DESIGN: Mice with cerebrally inoculated Ehrlich ascites tumor (EHR2) cells were treated with combinations of etoposide + dexrazoxane + cerebral radiotherapy.
  • This indicates a direct dexrazoxane modulation of the combined effects of etoposide and radiation in brain tumors.
  • CONCLUSION: Combining etoposide (high or normal doses) and dexrazoxane synergizes with cerebral radiotherapy and significantly improves survival in mice with central nervous system tumors.
  • This regimen may thus improve radiation therapy of central nervous system tumors.
  • [MeSH-minor] Animals. Blood-Brain Barrier / drug effects. Blood-Brain Barrier / pathology. Blood-Brain Barrier / radiation effects. Combined Modality Therapy. DNA Damage. DNA, Neoplasm / drug effects. DNA, Neoplasm / genetics. DNA, Neoplasm / radiation effects. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Mice. Mice, Inbred Strains. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology. Neoplasms, Experimental / radiotherapy. Razoxane / administration & dosage. Survival Analysis. Time Factors. Treatment Outcome. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166453.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 5AR83PR647 / Razoxane; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


31. Choudhury SM, Gupta M, Majumder UK: Antineoplastic activities of MT81 and its structural analogue in Ehrlich ascites carcinoma-bearing Swiss Albino mice. Oxid Med Cell Longev; 2010 Jan-Feb;3(1):61-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineoplastic activities of MT81 and its structural analogue in Ehrlich ascites carcinoma-bearing Swiss Albino mice.
  • Luteoskyrin,a hydroxyanthraquinone has been proved to be a potent inhibitor against Ehrlich ascites tumor cells.
  • The comparative antitumor activity and antioxidant status of MT81 and its structural analogue [Acetic acid-MT81 (Aa-MT81)] having polyhydroxyanthraquinone structure were assessed against Ehrlich ascites carcinoma (EAC) tumor in mice.
  • In in vivo study, MT81 and its structural analogue were administered (i.p.) at the two different doses (5, 7 mg MT81; 8.93, 11.48 mg Aa-MT81/kg body weight) for 7 days after 24 hrs. of tumor inoculation.
  • The activities were assessed using mean survival time (MST), increased life span (ILS), tumor volume, viable tumor cell count, peritoneal cell count, protein percentage and hematological parameters.
  • They decreased the tumor volume, viable tumor cell count, hemoglobin percentage and packed cell volume.
  • [MeSH-major] Anthraquinones / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 1997;44(5):329-33 [9473795.001]
  • [Cites] Chem Phys Lipids. 1987 Nov-Dec;45(2-4):337-51 [3319232.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Oncol. 2007 Sep;31(3):663-9 [17671695.001]
  • [Cites] Phytother Res. 2008 Aug;22(8):1097-103 [18570233.001]
  • [Cites] Mol Pharmacol. 2008 Oct;74(4):1132-40 [18635669.001]
  • [Cites] Phytomedicine. 2009 Mar;16(2-3):188-97 [19150236.001]
  • [Cites] Chem Biol Interact. 2009 May 15;179(2-3):145-53 [19161993.001]
  • [Cites] Clin Biochem. 1999 Nov;32(8):595-603 [10638941.001]
  • [Cites] J Ethnopharmacol. 2000 Jul;71(1-2):349-52 [10904185.001]
  • [Cites] Indian J Exp Biol. 1988 Apr;26(4):315-22 [3169853.001]
  • [Cites] J Biol Chem. 1988 Nov 25;263(33):17205-8 [3053703.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(4):264-7 [2752509.001]
  • [Cites] Int J Cancer. 1989 Dec 15;44(6):1028-33 [2558077.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1431-9 [2302708.001]
  • [Cites] Free Radic Biol Med. 1990;8(6):583-99 [2193855.001]
  • [Cites] Br J Hosp Med. 1990 May;43(5):334-44 [2194616.001]
  • [Cites] Pharmazie. 1992 Apr;47(4):288-91 [1518888.001]
  • [Cites] Indian J Exp Biol. 1992 Feb;30(2):140-1 [1521863.001]
  • [Cites] Indian J Exp Biol. 1993 Nov;31(11):888-90 [8112762.001]
  • [Cites] Planta Med. 1994 Apr;60(2):106-9 [8202557.001]
  • [Cites] J Antibiot (Tokyo). 1997 Feb;50(2):111-8 [9099219.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Indian J Exp Biol. 1997 May;35(5):473-7 [9378516.001]
  • [Cites] Adv Cancer Res. 1954;2:229-53 [13180440.001]
  • [Cites] Adv Cancer Res. 1958;5:199-290 [13533058.001]
  • [Cites] Prog Clin Cancer. 1965;10:625-63 [14283934.001]
  • [Cites] Cancer Lett. 2004 Dec 28;216(2):165-73 [15533592.001]
  • [Cites] J Antibiot (Tokyo). 2004 Nov;57(11):748-54 [15712670.001]
  • [Cites] J Ethnopharmacol. 2000 Sep;72(1-2):151-6 [10967466.001]
  • [Cites] Nature. 2001 May 17;411(6835):390-5 [11357148.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):115-25 [11597785.001]
  • [Cites] J Nat Prod. 2002 May;65(5):742-4 [12027756.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(4):309-14 [12111715.001]
  • [Cites] Pharmazie. 2004 Jan;59(1):42-9 [14964421.001]
  • [Cites] Med Oncol. 2004;21(1):21-30 [15034210.001]
  • [Cites] Experientia. 1967 Dec 15;23(12):1001-2 [6077857.001]
  • [Cites] J Antibiot (Tokyo). 1968 Jul;21(7):463-4 [4303502.001]
  • [Cites] Jpn J Exp Med. 1971 Jun;41(3):177-88 [5314585.001]
  • [Cites] Eur J Biochem. 1974 Sep 16;47(3):469-74 [4215654.001]
  • [Cites] Cancer Chemother Pharmacol. 1979;2(3):181-2 [455572.001]
  • [Cites] Biochem Pharmacol. 1980 Jan 1;29(1):19-26 [6244827.001]
  • [Cites] Anal Biochem. 1980 Jul 15;106(1):207-12 [7416462.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):95-102 [7071611.001]
  • [Cites] J Med Chem. 1982 May;25(5):579-89 [7086845.001]
  • [Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]
  • [Cites] J Med Chem. 1976 Nov;19(11):1339-42 [1003414.001]
  • (PMID = 20716929.001).
  • [ISSN] 1942-0994
  • [Journal-full-title] Oxidative medicine and cellular longevity
  • [ISO-abbreviation] Oxid Med Cell Longev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Antineoplastic Agents; 4Y8F71G49Q / Malondialdehyde; 82197-56-6 / MT81 mycotoxin; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione
  • [Other-IDs] NLM/ PMC2835890
  •  go-up   go-down


32. Hirai M, Minematsu H, Kondo N, Oie K, Igarashi K, Yamazaki N: Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun; 2007 Feb 16;353(3):553-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging.
  • We prepared the liposome binding Sialyl Lewis X (SLX) on the surface in order to specifically and efficiently deliver substances (fluorescent materials, chemical substances, proteins, genes, etc.) to inflammation or tumor regions.
  • The liposome with SLX (SLX-Lipo-Cy5.5), in which fluorescent substance Cy5.5 was included, was administered intravenously to arthritis or Ehrlich Ascites Tumor (EAT) bearing mouse, and the accumulation of liposome was observed using two types of in vivo fluorescent imaging equipment.
  • The result was that the accumulation of SLX-Lipo-Cy5.5 to inflammation or tumor regions was significantly higher than the control liposome without sugar chain (Lipo-Cy5.5) at 24 and 48 h after administration.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / metabolism. Inflammation / metabolism. Lewis Blood-Group System. Liposomes / pharmacokinetics. Oligosaccharides / administration & dosage

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189617.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / CY5.5 cyanine dye; 0 / Carbocyanines; 0 / Fluorescent Dyes; 0 / Lewis Blood-Group System; 0 / Liposomes; 0 / Oligosaccharides
  •  go-up   go-down


33. Chekulayeva LV, Chekulayev VA, Shevchuk IN: Active oxygen intermediates in the degradation of hematoporphyrin derivative in tumor cells subjected to photodynamic therapy. J Photochem Photobiol B; 2008 Nov 13;93(2):94-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active oxygen intermediates in the degradation of hematoporphyrin derivative in tumor cells subjected to photodynamic therapy.
  • Prior studies suggested that upon PDT the photobleaching of HPD in tumor tissues is largely mediated by self-sensitized singlet oxygen.
  • The main aim of this work was to clarify the significance of H2O2, superoxide (O2.(-)) and hydroxyl (OH.) radicals in bleaching of HPD in tumor cells subjected to PDT.
  • Experiments were performed on Ehrlich ascites carcinoma (EAC) cells, which were loaded with HPD in PBS and then irradiated with red light at 630 nm in the same buffer.
  • Model experiments suggest that PPO could also participate in bleaching of HPD in tumors treated with PDT.
  • It was found that HPD may destroy in tumor cells after cessation of photoirradiation and that this event is largely mediated by the presence of H2O2, a precursor of OH(.).
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Hematoporphyrin Derivative / metabolism. Photochemotherapy

  • Hazardous Substances Data Bank. Deuterium oxide .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760622.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Reactive Oxygen Species; 68335-15-9 / Hematoporphyrin Derivative; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; J65BV539M3 / Deuterium Oxide
  •  go-up   go-down


34. Sadzuka Y, Iwasaki F, Sugiyama I, Horiuchi K, Hirano T, Ozawa H, Kanayama N, Sonobe T: Study on liposomalization of zinc-coproporphyrin I as a novel drug in photodynamic therapy. Int J Pharm; 2007 Jun 29;338(1-2):306-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 2 and 6h post-injection of ZnCPI liposome (pH 4.6), the ZnCPI concentration in the plasma of Ehrlich ascites carcinoma bearing mice was shown to be higher compared to that in other groups.
  • The ZnCPI concentrations in the tumor after 2 and 6h of ZnCPI liposome (pH 4.6) treatment were shown to be higher than that in other groups.
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Hydrogen-Ion Concentration. Liposomes / chemistry. Male. Mice. Photochemistry. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349754.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Coproporphyrins; 0 / Liposomes; 531-14-6 / coproporphyrin I
  •  go-up   go-down


35. Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME: Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine. Oncology; 2007;73(5-6):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis and staging of the disease was done by medical thoracoscopy with biopsies of the right pleura in December 2003, when he was treated with talc pleurodesis.
  • After 8 cycles, the patient presented renal toxicity limiting further cisplatinum chemotherapy and disease progression with peritoneal invasion of the tumor and ascites.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18523361.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Teixeira AS, Araújo FA, Ferreira MA, Barcelos LS, Teixeira MM, Andrade SP: Angiogenesis and inflammation in skeletal muscle in response to ascites tumor in mice. Life Sci; 2006 Feb 28;78(14):1637-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and inflammation in skeletal muscle in response to ascites tumor in mice.
  • This study addresses the interaction between Ehrlich ascites tumor and skeletal abdominal muscle, presenting quantitative analysis of ascites-induced angiogenesis and inflammation in this tissue of mice bearing-tumor.
  • Time-dependent changes in the muscle (cellular activity, angiogenesis, inflammation and cytokines production) were assessed by morphometric, functional, and biochemical parameters at days 1, 4 and 8 after i.p. inoculation of Ehrlich tumor cells (2.5 x 10(7)).
  • Likewise, the inflammatory process in the muscle, as assessed by myeloperoxidase (MPO) and n-acethylglucosaminidase (NAG) activities and the levels of the chemokines, keratinocyte-derived chemokine (CXC1-3/KC) and macrophage-chemoattractant protein (CCL2/MCP-1) increased with tumor development.
  • The combination of techniques used to describe angiogenesis and inflammation in a muscle model system has proved to be suited for quantitative measurements of microvascular changes and cellular infiltration occurring in the abdominal muscle wall of ascites-bearing mice.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / complications. Muscle, Skeletal / blood supply. Myositis / etiology. Neovascularization, Pathologic / etiology

  • MedlinePlus Health Information. consumer health - Myositis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313924.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hemoglobins
  •  go-up   go-down


37. Esteves-Souza A, Lucio KA, Da Cunha AS, Da Cunha Pinto A, Da Silva Lima EL, Camara CA, Vargas MD, Gattass CR: Antitumoral activity of new polyamine-naphthoquinone conjugates. Oncol Rep; 2008 Jul;20(1):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All compounds were active against human lines of promyelocytic leukemia (HL-60), lung cancer (GLC4), Burkitt lymphoma (Daudi) and a mouse breast tumor (Ehrlich carcinoma), but only unprotected 6a-c showed activity against the human line of melanoma (MV-3).
  • In conclusion, spermidine-1,4-naphthoquinone conjugates exhibited an increase in activity compared with the natural products and induced apoptosis of tumor cell lines by a mechanism that is mediated, at least in part, by ROS production.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. DNA Fragmentation / drug effects. Humans. Mice. Reactive Oxygen Species / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575741.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Polyamines; 0 / Reactive Oxygen Species
  •  go-up   go-down


38. Orsolić N, Kosalec I, Basić I: Synergistic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour. Biol Pharm Bull; 2005 Apr;28(4):694-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour.
  • Effect of two preparation (Croatian and Brazilian) of water-soluble derivative of propolis (WSDP), caffeic acid, quercetin, chrysin, naringenin (components present in WSDP) on the development of Ehrlich ascites tumour (EAT) was evaluated.
  • It was observed that all test compounds effectively inhibited tumour growth and the proliferation of EAT.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Flavonoids / pharmacology. Phenols / pharmacology. Propolis / pharmacology

  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. CAFFEIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802812.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Caffeic Acids; 0 / Flavanones; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 3CN01F5ZJ5 / chrysin; 9009-62-5 / Propolis; 9IKM0I5T1E / Quercetin; HN5425SBF2 / naringenin; U2S3A33KVM / caffeic acid
  •  go-up   go-down


39. Raman N, Jeyamurugan R, Senthilkumar R, Rajkapoor B, Franzblau SG: In vivo and in vitro evaluation of highly specific thiolate carrier group copper(II) and zinc(II) complexes on Ehrlich ascites carcinoma tumor model. Eur J Med Chem; 2010 Nov;45(11):5438-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo and in vitro evaluation of highly specific thiolate carrier group copper(II) and zinc(II) complexes on Ehrlich ascites carcinoma tumor model.
  • In vivo and in vitro antitumor functions of the complexes against Ehrlich ascites carcinoma tumor model have been investigated.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / pathology. Copper / chemistry. Sulfhydryl Compounds / pharmacology. Zinc / chemistry

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20864225.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Schiff Bases; 0 / Sulfhydryl Compounds; 789U1901C5 / Copper; 9007-49-2 / DNA; J41CSQ7QDS / Zinc
  •  go-up   go-down


40. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med; 2009 Jul 20;7:63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-kappaB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-kappaB activity and upregulating cytokine secretion - events that are known to promote tumor progression.
  • METHODS: EOC cells isolated from either ascites or tumor tissue were treated with increasing concentrations of ARRY-520 or Paclitaxel and cell viability determined.
  • IL-6), which promote chemoresistance and tumor progression.
  • ARRY-520 has similar anti-tumor activity in EOC cells as that of Paclitaxel.
  • However, unlike Paclitaxel, it does not induce these pro-tumor effects in Type I cells.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 2000 Jun;12(6):547-54 [10843728.001]
  • [Cites] Eur J Immunol. 2001 Aug;31(8):2448-57 [11500829.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 1):3-8 [11840413.001]
  • [Cites] Sci STKE. 1999 Oct 26;1999(5):RE1 [11865184.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13430-7 [11832478.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2611-20 [12730675.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3276-80 [15126370.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):35047-52 [15173176.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1159-69 [8548803.001]
  • [Cites] J Soc Gynecol Investig. 1994 Jul-Sep;1(3):181-90 [9419769.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3532-42 [16193064.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):599-608 [16388521.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3859-68 [16585214.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37 [16931107.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):689-98 [17101792.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):237-45 [17210704.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55 [18193114.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):182-8 [18479806.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4712-23 [18408758.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Aug;8(6):698-704 [18690830.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer. 2009 Jul 15;115(14):3204-16 [19472400.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19555-64 [11278851.001]
  • (PMID = 19619321.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118678-03; United States / NCI NIH HHS / CA / R01 CA118678; United States / NCI NIH HHS / CA / R01 CA118678-03; United States / NCI NIH HHS / CA / R01CA118678
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARRY 520; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / KIF11 protein, human; 0 / Thiadiazoles; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9; EC 3.6.1.- / Kinesin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2719595
  •  go-up   go-down


41. Klausen TK, Hougaard C, Hoffmann EK, Pedersen SF: Cholesterol modulates the volume-regulated anion current in Ehrlich-Lettre ascites cells via effects on Rho and F-actin. Am J Physiol Cell Physiol; 2006 Oct;291(4):C757-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholesterol modulates the volume-regulated anion current in Ehrlich-Lettre ascites cells via effects on Rho and F-actin.
  • In Ehrlich-Lettre ascites (ELA) cells, a current with biophysical and pharmacological properties characteristic of VRAC was activated by hypotonic swelling.
  • [MeSH-major] Actins / metabolism. Anions / metabolism. Carcinoma, Ehrlich Tumor / pathology. Carcinoma, Ehrlich Tumor / physiopathology. Cholesterol / metabolism. Ion Channels / metabolism. rho GTP-Binding Proteins / metabolism
  • [MeSH-minor] Amides / pharmacology. Animals. Bicyclo Compounds, Heterocyclic / pharmacology. Cell Line, Tumor. Cell Size. Chloride Channels / metabolism. Electric Conductivity. Enzyme Inhibitors / pharmacology. Hypotonic Solutions / pharmacology. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Phosphatidylinositol 4,5-Diphosphate. Phosphatidylinositol Phosphates / pharmacology. Polymers / metabolism. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Pyridines / pharmacology. Thiazoles / pharmacology. Thiazolidines. rho-Associated Kinases

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687471.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Amides; 0 / Anions; 0 / Bicyclo Compounds, Heterocyclic; 0 / Chloride Channels; 0 / Enzyme Inhibitors; 0 / Hypotonic Solutions; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ion Channels; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Phosphatidylinositol Phosphates; 0 / Polymers; 0 / Pyridines; 0 / Thiazoles; 0 / Thiazolidines; 138381-45-0 / Y 27632; 76343-94-7 / latrunculin B; 97C5T2UQ7J / Cholesterol; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


42. Wu FY, Huang GS, Jiang JW, Wang F, Xu XD, Peng DY: [Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov;29(11):2251-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu].
  • OBJECTIVE: To investigate the inhibitory effect of survivin antisense oligodeoxynucleotides (ASODN) mediated by polyethylenimine(PEI) on the proliferation of hepatocellular carcinoma SMMC-7721 cells, and assess its detect on the chemosensitivity of the cells to 5-FU.
  • In mice bearing transplanted hepatocarcinoma and ascites tumor derived from H22 cells, 5-FU combined with PEI-ASODN was administered, and the weight and volume of the subcutaneous tumors were measured to calculate the tumor inhibition rate, and the average survival time of the mice was calculated.
  • The tumor weight and volume were reduced in all the treated groups.
  • The tumor inhibition rate was 56.91% and volume inhibition rate was 57.83% in 5-FU+PEI-ASODN group, significantly different from those in the normal saline group (P<0.01).
  • In mice bearing ascites tumor, the average survival time was 22.0 days in saline group, and 42.7 days 5-FU+PEI-ASODN group.
  • CONCLUSION: PEI-ASODN complex can significantly inhibit the proliferation of hepatocarcinoma SMMC-7721 cells and enhance the chemosensitivity of the tumor cells to 5-FU.
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Synergism. Humans. Mice

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923081.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Birc5 protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Repressor Proteins; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L: Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol; 2006 Nov;33(8):1065-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight weeks after the last injection, the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.
  • RESULTS: The tumor-free fractions of animals were 56% and 41% when treated with approximately 800 kBq and 3x approximately 267 kBq (211)At-MX35 F(ab')(2), respectively; 39% and 28% when treated with approximately 400 kBq and 3x approximately 133 kBq (211)At-MX35 F(ab')(2), respectively; and 17% and 22% when treated with approximately 50 kBq or 3x approximately 17 kBq (211)At-MX35 F(ab')(2), respectively.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Mice

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127181.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 211At-labeled monoclonal antibody MX35; 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fab Fragments; 0 / Organometallic Compounds
  •  go-up   go-down


44. Pan XQ, Lee RJ: In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res; 2005 Jan-Feb;25(1A):343-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Folate receptor (FR) is selectively amplified among human tumors, including in 70% of myeloid leukemias.
  • FR-targeted liposomal delivery is an attractive strategy for enhancing the therapeutic efficacy of anticancer agents against FR(+) tumors.
  • In this study, FR-targeted liposomal daunorubicin was evaluated in an FR+ L1210JF murine ascites tumor model for therapeutic efficacy in vivo.
  • For in vivo therapeutic study, B6D2F1 mice on a folate-free diet were intraperitoneally implanted with FR (+) L1210JF cells and treated with 4 intraperitoneal injections of 10 mg/kg liposomal DNR at 1, 5, 9 and 13 days following tumor cell inoculation.
  • In the therapeutic study, mice treated with F-L-DNR showed significantly greater tumor inhibition and 40.7% greater increase in life-span compared to those that received identical doses of L-DNR.
  • [MeSH-minor] Animals. Ascites / metabolism. Fluorescent Dyes / administration & dosage. Fluorescent Dyes / pharmacokinetics. Folate Receptors, GPI-Anchored. Liposomes / administration & dosage. Liposomes / chemistry. Liposomes / pharmacokinetics. Male. Mice. Mice, Inbred DBA. Phosphatidylcholines / administration & dosage. Phosphatidylcholines / chemistry. Phosphatidylcholines / pharmacokinetics. Phosphatidylethanolamines / administration & dosage. Phosphatidylethanolamines / chemistry. Phosphatidylethanolamines / pharmacokinetics. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / chemistry. Polyethylene Glycols / pharmacokinetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816557.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA095673; United States / NCI NIH HHS / CA / R01CA79758; United States / NCI NIH HHS / CA / R43CA102847; United States / NCI NIH HHS / CA / R43CA81975
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Fluorescent Dyes; 0 / Folate Receptors, GPI-Anchored; 0 / Liposomes; 0 / Phosphatidylcholines; 0 / Phosphatidylethanolamines; 0 / Receptors, Cell Surface; 043IPI2M0K / 1,2-distearoyllecithin; 30IQX730WE / Polyethylene Glycols; 39382-08-6 / phosphatidylethanolamine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


45. Ramachandra S, D'Souza SS, Gururaj AE, Shaila MS, Salimath BP: Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. J Gene Med; 2009 May;11(5):422-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo.
  • A soluble form of Flt-1, a VEGF receptor, is potentially useful as an antagonist of VEGF, and accumulating evidence suggests the applicability of sFlt-1 in tumor suppression.
  • In the present study, we have developed and tested strategies targeted specifically to VEGF for the treatment of ascites formation.
  • METHODS: As an initial strategy, we produced recombinant sFLT-1 in the baculovirus expression system and used it as a trap to sequester VEGF in the murine ascites carcinoma model.
  • The effect of the treatment on the weight of the animal, cell number, ascites volume and proliferating endothelial cells was studied.
  • The second strategy involved, producing Ehrlich ascites tumor (EAT) cells stably transfected with vectors carrying cDNA encoding truncated form of Flt-1 and using these cells to inhibit ascites tumors in a nude mouse model.
  • RESULTS: The sFLT-1 produced by the baculovirus system showed potent anti-angiogenic activity as assessed by rat cornea and tube formation assay. sFLT-1 treatment resulted in reduced peritoneal angiogenesis with a concomitant decrease in tumor cell number, volume of ascites, amount of free VEGF and the number of invasive tumor cells as assayed by CD31 staining.
  • EAT cells stably transfected with truncated form of Flt-1 also effectively reduced the tumor burden in nude mice transplanted with these cells, and demonstrated a reduction in ascites formation and peritoneal angiogenesis.
  • CONCLUSIONS: The inhibition of peritoneal angiogenesis and tumor growth by sequestering VEGF with either sFlt-1 gene expression by recombinant EAT cells or by direct sFLT-1 protein therapy is shown to comprise a potential therapy.
  • [MeSH-major] Ascites / pathology. Ascites / therapy. Paracrine Communication. Transfection. Vascular Endothelial Growth Factor Receptor-1 / genetics. Vascular Endothelial Growth Factor Receptor-1 / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19266483.001).
  • [ISSN] 1521-2254
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


46. Badria FA, Ameen M, Akl MR: Evaluation of cytotoxic compounds from calligonum comosum L. growing in Egypt. Z Naturforsch C; 2007 Sep-Oct;62(9-10):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The total methanolic extract and other fractions were tested for their anticancer activity using Ehrlich ascites, brine shrimp and antioxidant assays.
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor. Cell Survival / drug effects. Desert Climate. Egypt. Mice. Plant Extracts / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069236.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Plant Extracts
  •  go-up   go-down


47. Yu J, Liu H, Lei J, Tan W, Hu X, Zou G: Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res; 2007 Sep;21(9):817-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 60 mg/kg/day, CE-SB significantly inhibited the solid tumor proliferation and increased the life span of ascites tumor bearing mice (p < 0.01).
  • [MeSH-minor] Animals. Cell Line, Tumor / drug effects. Electrophoresis, Agar Gel. Flow Cytometry. Humans. Inhibitory Concentration 50. Male. Medicine, Chinese Traditional. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674423.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


48. Mandal A, Batabyal SK, Poddar MK: Long-term caffeine-induced inhibition of EAC cell progression in relation to gonadal hormonal status. Indian J Exp Biol; 2007 Apr;45(4):347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitory action of caffeine (a tri-methylxanthine alkaloid) on progression or pathogenesis of lung, breast and ovarian cancer including Ehrlich ascites carcinoma (EAC) cell development has been reported.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477306.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 3G6A5W338E / Caffeine
  •  go-up   go-down


49. de Souza AR, Coelho EP, Zyngier SB: Comparison of the anti-neoplastic effects of dirhodium(II) tetrapropionate and its adducts with nicotinate and isonicotinate anions in mice bearing Ehrlich tumors. Eur J Med Chem; 2006 Oct;41(10):1214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the anti-neoplastic effects of dirhodium(II) tetrapropionate and its adducts with nicotinate and isonicotinate anions in mice bearing Ehrlich tumors.
  • The compound effects on the survival rate of mice bearing Ehrlich ascites tumors were tested and presented in the form of a survival table, and analyzed by the Mantel-Haenszel chi-square test for N animals in each group.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Isonicotinic Acids / chemistry. Niacin / chemistry. Organometallic Compounds / pharmacology. Propionates / chemistry. Rhodium / chemistry

  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. RHODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822594.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anions; 0 / Antineoplastic Agents; 0 / Isonicotinic Acids; 0 / Organometallic Compounds; 0 / Propionates; 2679MF687A / Niacin; DMK383DSAC / Rhodium
  •  go-up   go-down


50. Quinteiro-Filho WM, Righi DA, Palermo-Neto J: Effect of cyhalothrin on Ehrlich tumor growth and macrophage activity in mice. Braz J Med Biol Res; 2009 Oct;42(10):912-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cyhalothrin on Ehrlich tumor growth and macrophage activity in mice.
  • Macrophages are key elements in cellular immune responses and operate at the tumor-host interface.
  • This study investigated the relationship among cyhalothrin effects on Ehrlich tumor growth, serum corticosterone levels and peritoneal macrophage activity in mice.
  • Cyhalothrin i) increased Ehrlich ascitic tumor growth after ip administration of 5.0 x 106 tumor cells, i.e., ascitic fluid volume (control = 1.97 +/- 0.39 mL and experimental = 2.71 +/- 0.92 mL; P < 0.05), concentration of tumor cells/mL in the ascitic fluid (control = 111.95 +/- 16.73 x 106 and experimental = 144.60 +/- 33.18 x 106; P < 0.05), and total number of tumor cells in the ascitic fluid (control = 226.91 +/- 43.22 x 106 and experimental = 349.40 +/- 106.38 x 106; P < 0.05);.
  • These data provide evidence that cyhalothrin simultaneously alters host resistance to Ehrlich tumor growth, hypothalamic-pituitary-adrenocortical (HPA) axis function, and peritoneal macrophage activity.
  • The results are discussed in terms of data suggesting a link between stress, HPA axis activation and resistance to tumor growth.

  • Hazardous Substances Data Bank. CYHALOTHRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784476.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Insecticides; 0 / Nitriles; 0 / Pyrethrins; V0V73PEB8M / cyhalothrin; W980KJ009P / Corticosterone
  •  go-up   go-down


51. Fomenko EIu, Slepov EV, Inzhevatkin EV, Savchenko AA: [Bioluminescent method for determination of concentration metabolic substrates and NAD+ in the lymphocytes]. Biomed Khim; 2006 Sep-Oct;52(5):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have developed a new bioluminescent method for determination of concentrations of pyruvate, lactate, malate, glutamate and NAD+ in the periferal blood lymphocytes from mice with Ehrlich ascites carcinoma.
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor / metabolism. Mice. Mice, Inbred ICR

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180925.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0U46U6E8UK / NAD
  •  go-up   go-down


52. Ghosh S, Das Sarma M, Patra A, Hazra B: Anti-inflammatory and anticancer compounds isolated from Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn. J Pharm Pharmacol; 2010 Sep;62(9):1158-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were then tested against a murine tumour (Ehrlich ascites carcinoma), and three human cancer cell lines, namely A375 (malignant skin melanoma), Hep2 (epidermoid laryngeal carcinoma) and U937 (lymphoma).
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Antioxidants / therapeutic use. Carrageenan. Cell Line, Tumor. Disease Models, Animal. Dose-Response Relationship, Drug. Edema / drug therapy. Edema / metabolism. Free Radicals / metabolism. Humans. Interferon-gamma. Lipopolysaccharides. Macrophages / drug effects. Mice. Neoplasms / drug therapy. Neoplasms / metabolism. Nitric Oxide Synthase Type II / antagonists & inhibitors. Phytotherapy

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20796195.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Free Radicals; 0 / Lipopolysaccharides; 0 / Plant Extracts; 0 / Quinones; 31C4KY9ESH / Nitric Oxide; 82115-62-6 / Interferon-gamma; 9000-07-1 / Carrageenan; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


53. Bromberg N, Dreyfuss JL, Regatieri CV, Palladino MV, Durán N, Nader HB, Haun M, Justo GZ: Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem Biol Interact; 2010 Jun 7;186(1):43-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor.
  • Herein, violacein, a natural indolic pigment extracted from Chromobacterium violaceum, was evaluated for its antitumoral potential against the Ehrlich ascites tumor (EAT) in vivo and in vitro.
  • Moreover, doses of 0.1 and 1.0 microg kg(-1) violacein, administered intraperitoneally (i.p.) to EAT-bearing mice throughout the lifespan of the animals significantly inhibited tumor growth and increased survival of mice.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Chromobacterium / chemistry. Indoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20416285.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Reactive Oxygen Species; 548-54-9 / violacein; GAN16C9B8O / Glutathione
  •  go-up   go-down


54. Upadhyay KK, Bhatt AN, Castro E, Mishra AK, Chuttani K, Dwarakanath BS, Schatz C, Le Meins JF, Misra A, Lecommandoux S: In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci; 2010 May 14;10(5):503-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, PolyDOC uptake in Ehrlich Ascites Tumor (EAT) tumor bearing mice was larger at each time point compared to DS, making such a polymer vesicle formulation an efficient drug nanocarrier for improved DOC cancer therapy.
  • [MeSH-minor] Animals. Capsules. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Rabbits

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232310.001).
  • [ISSN] 1616-5195
  • [Journal-full-title] Macromolecular bioscience
  • [ISO-abbreviation] Macromol Biosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Capsules; 0 / Delayed-Action Preparations; 0 / Taxoids; 0 / poly(gamma-benzyl glutamate)-b-hyaluronan; 15H5577CQD / docetaxel; 25513-46-6 / Polyglutamic Acid; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


55. Modesitt SC, Parsons SJ: In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Gynecol Oncol; 2010 Nov;119(2):351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endpoints were survival, ascites and tumor weight.
  • CONCLUSIONS: The efficacy of the combination and sequence of vorinostat and paclitaxel administration was cell line dependent and suggests that responses vary based on tumor specific characteristics.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cyclin B / metabolism. Drug Synergism. Female. Histone Deacetylases / metabolism. Humans. Mice. Mice, Nude. Xenograft Model Antitumor Assays. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20673975.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Cyclin B; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / bcl-2-Associated X Protein; 58IFB293JI / vorinostat; EC 3.5.1.98 / Histone Deacetylases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


56. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A; 2010 Apr 27;107(17):7875-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
  • NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date.
  • In an effort to understand in vivo tolerance mechanisms, we assessed the phenotype and function of NY-ESO-1-specific CD8(+) T cells derived from peripheral blood lymphocytes (PBLs), tumor-infiltrating lymphocytes (TILs), and tumor-associated lymphocytes (TALs) of EOC patients with NY-ESO-1-expressing tumors, with or without humoral immunity to NY-ESO-1.
  • Compared with PBLs, tumor-derived NY-ESO-1-specific CD8(+) T cells demonstrated impaired effector function, preferential usage of dominant T-cell receptor, and enriched coexpression of inhibitory molecules LAG-3 and PD-1.
  • Expression of LAG-3 and PD-1 on CD8(+) T cells was up-regulated by IL-10, IL-6 (cytokines found in tumor ascites), and tumor-derived antigen-presenting cells.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Apoptosis Regulatory Proteins / metabolism. CD8-Positive T-Lymphocytes / metabolism. Gene Expression Regulation, Neoplastic / immunology. Lymphocytes, Tumor-Infiltrating / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):467-77 [18500231.001]
  • [Cites] Immunity. 2008 Mar;28(3):414-24 [18342010.001]
  • [Cites] PLoS One. 2008;3(10):e3409 [18923710.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):29-37 [19043418.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5240-9 [19380770.001]
  • [Cites] J Immunol. 2000 Jul 1;165(1):533-8 [10861093.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1709-18 [11527700.001]
  • [Cites] J Virol. 2003 Apr;77(8):4911-27 [12663797.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6076-83 [14522938.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1191-8 [14625547.001]
  • [Cites] Annu Rev Immunol. 2004;22:765-87 [15032596.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5450-5 [15100286.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Immunogenetics. 1997;47(1):96-8 [9382927.001]
  • [Cites] Annu Rev Immunol. 2005;23:515-48 [15771580.001]
  • [Cites] Immunology. 2005 Jun;115(2):170-8 [15885122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Nature. 2006 Feb 9;439(7077):682-7 [16382236.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):871-81 [16606666.001]
  • [Cites] Adv Exp Med Biol. 2007;590:185-93 [17191386.001]
  • [Cites] J Virol. 2007 Mar;81(6):2545-53 [17182670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42 [17652518.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):116-25 [18566376.001]
  • (PMID = 20385810.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Apoptosis Regulatory Proteins; 0 / CD223 antigen; 0 / CTAG1B protein, human; 0 / Cytokines; 0 / Membrane Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  • [Other-IDs] NLM/ PMC2867907
  •  go-up   go-down


57. Mandal D, Lahiry L, Bhattacharyya A, Bhattacharyya S, Sa G, Das T: Tumor-induced thymic involution via inhibition of IL-7R alpha and its JAK-STAT signaling pathway: protection by black tea. Int Immunopharmacol; 2006 Mar;6(3):433-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-induced thymic involution via inhibition of IL-7R alpha and its JAK-STAT signaling pathway: protection by black tea.
  • We found that in Ehrlich's ascites carcinoma (EAC)-bearing mice there was profound depletion of CD4+ and CD8+ cells in peripheral blood with severely damaged thymus on 21st day of tumor inoculation.
  • However, treatment with black tea at an antitumor dose of 2.5% significantly reduced such depletion and protected the thymus considerably from tumor onslaught.
  • Interestingly, black tea treatment prevented IL-7Ralpha down-regulation and protected the signaling cascade through JAK-STAT thereby inhibiting tumor-induced thymic apoptosis and ensuring proper functioning of this organ in tumor-bearing host.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / pathology. Carcinoma, Ehrlich Tumor / prevention & control. Janus Kinase 3 / antagonists & inhibitors. MAP Kinase Signaling System / immunology. Receptors, Interleukin-7 / antagonists & inhibitors. STAT5 Transcription Factor / antagonists & inhibitors. Tea. Thymus Gland / pathology
  • [MeSH-minor] Animals. Apoptosis / physiology. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / pathology. Camellia sinensis. Cell Line, Tumor. Cells, Cultured. Leukocyte Count. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / pathology. Lymphocyte Count. Mice. Phosphorylation. Plant Extracts / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428079.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Receptors, Interleukin-7; 0 / STAT5 Transcription Factor; 0 / Tea; 0 / interleukin-7 receptor, alpha chain; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


58. Turan T, Aykan B, Koc S, Boran N, Tulunay G, Karacay O, Erdogan Z, Kose F: Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori; 2006 Nov-Dec;92(6):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of metastatic ovarian tumors from extragenital primary sites.
  • AIMS AND BACKGROUND: The aim of this study was to evaluate patients with metastatic ovarian tumors from extragenital primary sites.
  • METHODS: The medical records of 75 patients were reviewed retrospectively for age at diagnosis, presenting symptoms, preoperative tumor marker levels, preoperative diagnostic workup, operative technique, intraoperative evaluation, frozen-section and pathology results, laterality of metastasis, and primary tumor site.
  • The specific impact of metastasis from colorectal and gastric primary sites on laterality, gross features and dimensions of ovarian mass, volume of ascites and tumor marker levels was investigated.
  • It was not possible to identify the primary tumor site in 8 (10.7%) patients.
  • Bilateral metastasis was found in 86.4% patients; 42.7% of the metastatic ovarian tumors were Krukenberg tumors; 50.7% of the ovarian masses were solid.
  • The mean preoperative serum levels of tumor markers were 298.7 U/mL, 178 U/mL and 113.3 U/mL for CA 125, CA 19-9 and CA 15-3, respectively.
  • The presence of ascites was more frequent in ovarian tumors originating from colorectal and gastric primaries.
  • CONCLUSIONS: Surgery is essential for the diagnosis of the primary tumor and necessary for relief of symptoms.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Digestive System Neoplasms / diagnosis. Lymphoma / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Ascites / etiology. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Frozen Sections. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260489.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


59. Chekulayeva L, Shevchuk I, Chekulayev V, Oginskaya E: Influence of heating on the activity of xanthine oxidase in tumor cells subjected to the phototoxic action of hematoporphyrin derivative. Neoplasma; 2007;54(3):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of heating on the activity of xanthine oxidase in tumor cells subjected to the phototoxic action of hematoporphyrin derivative.
  • The aim of this study was to clarify the mechanism of the stimulatory effect of heat stress on generation of superoxide radical (O2-*) in tumors subjected to photodynamic therapy (PDT) with hematoporphyrin derivative (HPD).
  • For this purpose, the effect of heating on the activity of xanthine oxidase (XOD) in tumor cells upon their photosensitization with HPD was examined; this enzyme is participated in purine catabolism and has the ability to generate O2-*, a precursor of H2O2 and very cytotoxic hydroxyl radical.
  • The study was carried out on Ehrlich ascites carcinoma (EAC) cells, which were loaded with HPD in a serum-free medium and then irradiated with red light (lambda max = 630 nm) at 3 different temperatures (30, 37 and 44 degrees C).
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / enzymology. Hematoporphyrin Derivative / therapeutic use. Hematoporphyrin Photoradiation. Hyperthermia, Induced. Photosensitizing Agents / therapeutic use. Xanthine Oxidase / metabolism
  • [MeSH-minor] Animals. Female. Hydrogen Peroxide / pharmacology. Hydroxyl Radical / metabolism. Mice. Oxidation-Reduction. Superoxides / metabolism. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447855.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 11062-77-4 / Superoxides; 3352-57-6 / Hydroxyl Radical; 68335-15-9 / Hematoporphyrin Derivative; BBX060AN9V / Hydrogen Peroxide; EC 1.17.3.2 / Xanthine Oxidase
  •  go-up   go-down


60. Tomsík P, Stoklasová A, Micuda S, Niang M, Suba P, Knízek J, Rezácová M: Evaluation of the antineoplastic activity of L-rhamnose in vitro. A comparison with 2-deoxyglucose. Acta Medica (Hradec Kralove); 2008;51(2):113-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of unsubstituted deoxyhexoses, 2-deoxy-D-glucose (2-DG) and L-fucose, on tumor cells has been reported in several papers throughout the last decades.
  • In the present study, we examined the effect of L-rhamnose on DNA and protein synthesis, growth and the potential induction of apoptosis of tumor cells in vitro.
  • Using 2-DG for comparison, we studied the effect of L-rhamnose in concentrations up to 20 (32 resp.) mmol/l on the initial velocity of the incorporation of labeled precursors of DNA and proteins in short term cultures of both mouse Ehrlich ascites tumor (EAT) and human HL-60 cells in vitro, and further, on cell proliferation and apoptosis induction in HL-60 cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998363.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lamin Type B; 9G2MP84A8W / Deoxyglucose; QN34XC755A / Rhamnose
  •  go-up   go-down


61. Guruvayoorappan C, Kuttan G: Immunomodulatory and antitumor activity of Biophytum sensitivum extract. Asian Pac J Cancer Prev; 2007 Jan-Mar;8(1):27-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extract was 100% toxic at a concentration of 0.5 mg/ml to Dalton's lymphoma ascites (DLA) and Ehrlich ascites carcinoma (EAC) cells. B. sensitivum extract was also found to be cytotoxic towards L929 cells in culture at a concentration of 0.1 mg/ml.
  • Administration of B. sensitivum extract (500 microg/dose/animal) could inhibit the solid tumor development in mice induced with DLA cells and increase the lifespan of mice bearing Ehrlich ascites carcinoma tumors by 93.3%. B. sensitivum treatment significantly (p<0.001) reduced the tumor cell glutathione (GSH) levels as well as serum gamma glutamyl transpeptidase (GGT) and nitric oxide (NO) levels in ascites tumor bearing animals.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Ascites / drug therapy. Carcinoma, Ehrlich Tumor / drug therapy. Lymphoma / drug therapy. Phytotherapy. Plant Extracts / therapeutic use. Plants, Medicinal / chemistry
  • [MeSH-minor] Animals. Erythrocytes / drug effects. Glutathione / metabolism. Mice. Mice, Inbred BALB C. Nitric Oxide / blood. Sheep. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477767.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 31C4KY9ESH / Nitric Oxide; GAN16C9B8O / Glutathione
  •  go-up   go-down


62. Li Y, Li Y, Niu X, Jie L, Shang X, Guo J, Li Q: Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride. J Inorg Biochem; 2008 Sep;102(9):1731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride.
  • Reaction of di-n-butyltin(IV) dichloride with 4-chlorobenzohydroxamic acid at 1:1 ratio yielded a new mixed-ligand diorganotin(IV) complex, di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride(DBDCT).
  • DBDCT exhibited strong in vitro cytotoxic activity toward human immature granulocyte leukemia (HL-60), human salivary-gland carcinoma (SGC-7901), human henrietta carcinoma (Hela) and human urinary bladder (T24) cell lines which, in some cases, were equal to, or even higher than those of cis-dichlorodiammineplatinum(II) (cisplatin, DDP), the widely clinically used drug.
  • The further in vivo antitumor tests of DBDCT towards the transplantation tumor models of sarcoma carcinoma (S(180)), hepatocellular carcinoma (H(22)) and Ehrlich's ascites carcinoma (EAC) on mice were carried out via injection intraperitoneally with cisplatin as positive contrast drug.
  • The results showed that DBDCT displayed in vivo antitumor activity against the hepatocellular carcinoma H(22) and sarcoma carcinoma S(180) which were close to those of cisplatin, meanwhile, the survival-extending rates at middle dose and high dose on mice Ehrlich's ascites tumor EAC were higher than those of cisplatin, and there was a good dose-effect relationship.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Crystallography, X-Ray. HL-60 Cells. HeLa Cells. Humans. Magnetic Resonance Spectroscopy. Mice. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573534.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organotin Compounds
  •  go-up   go-down


63. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res; 2005 Mar 15;65(6):2457-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option.
  • Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses.
  • Finally, regulatory T cells were analyzed in tumors and ascites from patients with HCC.
  • There were also high numbers of regulatory T cells in tumor-infiltrating lymphocytes of HCC patients comparable with the increase in their peripheral blood.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Carcinoma, Hepatocellular / immunology. Liver Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781662.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Receptors, Interleukin-2
  •  go-up   go-down


64. Thakur GA, Shaikh MM: Synthesis, characterization, antibacterial and cytotoxicity studies on some mixed ligand Th(IV) complexes. Acta Pol Pharm; 2006 Mar-Apr;63(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The representative complex has been screened for cytotoxicity (IC50) studies against Ehrlich ascites cells and Daltons lymphoma ascites cells and shows low cytotoxic activity.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / drug effects. Drug Evaluation, Preclinical / methods. Escherichia coli / drug effects. Ligands. Models, Chemical. Molecular Structure. Staphylococcus aureus / drug effects. Thermodynamics

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. THORIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514871.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Ligands; 60YU5MIG9W / Thorium
  •  go-up   go-down


65. Suntres ZE, Lui EM: Prooxidative effect of copper--metallothionein in the acute cytotoxicity of hydrogen peroxide in Ehrlich ascites tumour cells. Toxicology; 2006 Jan 16;217(2-3):155-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prooxidative effect of copper--metallothionein in the acute cytotoxicity of hydrogen peroxide in Ehrlich ascites tumour cells.
  • Hydrogen peroxide (H(2)O(2))-induced oxidative injury was examined in Ehrlich ascites tumour cells isolated from host mice pretreated with 0, 1 or 2mg of CuSO(4) (ip) 24h earlier.
  • Control Ehrlich cells contained low levels of Cu and Cu treatment produced dose-related increases in cellular Cu and Cu-MT levels and corresponding increases in sensitivity to oxidative toxicity of H(2)O(2) (LC(50), cell blebbing, lipid peroxidation, GSH depletion, and increase in intracellular free [Ca(2+)](i)).
  • [MeSH-minor] Animals. Calcium / metabolism. Carcinoma, Ehrlich Tumor / metabolism. Carcinoma, Ehrlich Tumor / pathology. Cell Survival / drug effects. Copper Sulfate / pharmacology. Deferoxamine / pharmacology. Dose-Response Relationship, Drug. Glutathione Disulfide / metabolism. Injections, Intraperitoneal. Iron / chemistry. Iron / metabolism. Lipid Peroxidation / drug effects. Male. Mannitol / pharmacology. Mice. Oxidative Stress / drug effects. Penicillamine / pharmacology. Pinocytosis / drug effects. Time Factors. Tumor Cells, Cultured. Zinc / chemistry. Zinc / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (D)-PENICILLAMINE .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. COPPER(II) SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221516.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 3OWL53L36A / Mannitol; 789U1901C5 / Copper; 9038-94-2 / Metallothionein; BBX060AN9V / Hydrogen Peroxide; E1UOL152H7 / Iron; GNN1DV99GX / Penicillamine; J06Y7MXW4D / Deferoxamine; J41CSQ7QDS / Zinc; LRX7AJ16DT / Copper Sulfate; SY7Q814VUP / Calcium; ULW86O013H / Glutathione Disulfide
  •  go-up   go-down


66. Yadav AK, Mishra P, Jain S, Mishra P, Mishra AK, Agrawal GP: Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target; 2008 Jul;16(6):464-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the present study was to synthesize core-corona nanoparticles of doxorubicin (DOX) using hyaluronic acid-polyethyleneglycol-polycaprolactone (HA-PEG-PCL) copolymer for tumor targeting.
  • The tissue distribution study and tumor growth inhibition were performed after intravenous injection of nanoparticles in Ehrlich ascites tumor (EAT)-bearing mice.
  • The nanoparticles of HA-PEG-PCL copolymer accomplishes efficient delivery of DOX in EAT tumor when compared with the MPEG-PCL nanoparticles by the process of receptor-mediated endocytosis, as well as enhanced permeability and retention effect.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Carcinoma, Ehrlich Tumor / pathology. Delayed-Action Preparations. Drug Carriers. Female. In Vitro Techniques. Mice. Rabbits. Rats. Rats, Sprague-Dawley. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604659.001).
  • [ISSN] 1029-2330
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Polyesters; 0 / hyaluronic acid-polyethyleneglycol-polycaprolactone copolymer; 80168379AG / Doxorubicin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


67. Li H, Lu X, Lu M, Liu H: Isolation, purification and antitumor activity of lipopolysaccharide from cow placenta. Int J Biol Macromol; 2008 Oct 1;43(3):232-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, LPS-PS-2 was evaluated for antitumor activity against Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice.
  • LPS-PS-2 caused significant (P<0.05) decrease in tumor volume, and viable cell count; and it prolonged the life span of EAC-tumor-bearing mice.
  • Further, administration of LPS-CP-2 reduced the tumor volume of both DLA and EAC cell lines in a dose-dependent way.
  • [MeSH-major] Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Lipopolysaccharides / isolation & purification. Lipopolysaccharides / pharmacology. Placenta / chemistry
  • [MeSH-minor] Animals. Cattle. Cell Line, Tumor. Cell Survival / drug effects. Female. Mice. Pregnancy. Pyrogens / metabolism. Rabbits

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582932.001).
  • [ISSN] 0141-8130
  • [Journal-full-title] International journal of biological macromolecules
  • [ISO-abbreviation] Int. J. Biol. Macromol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipopolysaccharides; 0 / Pyrogens
  •  go-up   go-down


68. Klausen TK, Bergdahl A, Hougaard C, Christophersen P, Pedersen SF, Hoffmann EK: Cell cycle-dependent activity of the volume- and Ca2+-activated anion currents in Ehrlich lettre ascites cells. J Cell Physiol; 2007 Mar;210(3):831-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle-dependent activity of the volume- and Ca2+-activated anion currents in Ehrlich lettre ascites cells.
  • Here, Cl- currents in Ehrlich Lettre Ascites (ELA) cells were monitored during cell cycle progression, under three conditions: (i) after osmotic swelling (i.e., VRAC), (ii) after an increase in the free intracellular Ca2+ concentration (i.e., the Ca2+-activated Cl- current, CaCC), and (iii) under steady-state isotonic conditions.
  • A novel high-affinity anion channel inhibitor, the acidic di-aryl-urea NS3728, which inhibited both VRAC and CaCC, attenuated ELA cell growth, suggesting a possible mechanistic link between cell cycle progression and cell cycle-dependent changes in the capacity for conductive Cl- transport.
  • [MeSH-minor] Animals. Calcium / metabolism. Carcinoma, Ehrlich Tumor / physiopathology. Cell Line, Tumor. Cell Proliferation / drug effects. Electrophysiology. Gene Expression Regulation / physiology. Mice. Osmosis / physiology. Patch-Clamp Techniques. Urea / analogs & derivatives. Urea / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17111356.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Clca1 protein, mouse; 0 / NS3728; 8W8T17847W / Urea; SY7Q814VUP / Calcium
  •  go-up   go-down


69. Günther T: Na+/Mg2+ antiport in non-erythrocyte vertebrate cells. Magnes Res; 2007 Jun;20(2):89-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments, results and conclusions on Na+/Mg2, antiport in lymphocytes, HL60 cells, Ehrlich ascites tumor cells, platelets, pancreatic acinar cells, sublingual acini, hepatocytes, ruminal epithelial cells, kidney cells, smooth muscle cells, heart muscle cells and skeletal muscle cells were reviewed.
  • [MeSH-minor] Animals. Biological Transport / physiology. Cell Line, Tumor. Cells, Cultured. HL-60 Cells. Homeostasis / physiology. Humans

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062583.001).
  • [ISSN] 0953-1424
  • [Journal-full-title] Magnesium research
  • [ISO-abbreviation] Magnes Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiporters; 9NEZ333N27 / Sodium; I38ZP9992A / Magnesium
  • [Number-of-references] 67
  •  go-up   go-down


70. Thippeswamy G, Sheela ML, Salimath BP: Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-&lt;kappa&gt;B and its DNA binding activity. Eur J Pharmacol; 2008 Jul 7;588(2-3):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is known that angiogenesis is involved in tumor growth and metastasis.
  • Our results showed that octacosanol (i) inhibits proliferation of endothelial cells and Ehrlich ascites tumor cells, (ii) inhibits neovascularization induced by angiogenic factors in chick chorioallantoic membrane and rat cornea in vivo angiogenesis assays, (iii) inhibits secretion of ascites fluid in the growing tumor cells in vivo.
  • Concerning the mechanism of action, octacosanol inhibited secretion of vascular endothelial growth factor into ascites fluid by the tumor cells.
  • The mechanism of inhibition of angiogenesis by octacosanol reflects on its effect on tumor angiogenesis and metastasis.
  • [MeSH-minor] Active Transport, Cell Nucleus / drug effects. Animals. Carcinoma, Ehrlich Tumor / drug therapy. Cell Proliferation / drug effects. Cells, Cultured. Chickens. Down-Regulation. Humans. Matrix Metalloproteinase Inhibitors. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513715.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Fatty Alcohols; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Vascular Endothelial Growth Factor A; 81I2215OVK / 1-octacosanol; 9007-49-2 / DNA
  •  go-up   go-down


71. Bala A, Kar B, Haldar PK, Mazumder UK, Bera S: Evaluation of anticancer activity of Cleome gynandra on Ehrlich's Ascites Carcinoma treated mice. J Ethnopharmacol; 2010 May 4;129(1):131-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anticancer activity of Cleome gynandra on Ehrlich's Ascites Carcinoma treated mice.
  • Traditionally the whole plant is used in the treatment of tumor, anti-inflammatory and lysosomal stability actions.
  • AIM OF STUDY: The objective of present study is to explore the anticancer activity of the methanol extract of the Cleome gynandra in Swiss albino mice against Ehrlich Ascites Carcinoma (EAC) cell line.
  • MATERIALS AND METHODS: Anticancer activity of methanol extract of Cleome gynandra (MECG) was evaluated in Swiss albino mice against Ehrlich Ascites Carcinoma (EAC) cell line at the doses of 200 and 400mg/kg body weight intraperitoneally.
  • Twenty-four hours of last dose and 18 h of fasting, the mice were sacrificed and antitumor effect of MECG assessed by evaluating tumor volume, viable and nonviable tumor cell count, tumor weight and hematological parameters of EAC bearing host.
  • RESULTS: MECG showed significant decrease in (p<0.01) tumor volume, viable cell count, tumor weight and elevated the life span of EAC tumor bearing mice.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Cell Proliferation / drug effects. Cleome. Phytotherapy. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20307641.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Hemoglobins; 0 / Plant Extracts
  •  go-up   go-down


72. El-Mowafy AM, Al-Gayyar MM, Salem HA, El-Mesery ME, Darweish MM: Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine; 2010 Dec 1;17(14):1067-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the chemotherapeutic/chemoenhancing effects of EGCG in mice bearing the solid Ehrlich ascites carcinoma (EAC) tumor, and jointly monitored levels of serum C-reactive protein (CRP), lipid peroxidation (as malondialdehyde: MDA) and leukocytosis (LC).
  • EGCG (20, 40 mg/kg) significantly shrank tumors (by 48% and 92%, respectively), and reduced LC, CRP and MDA levels.
  • Correlation studies showed positive association between tumor size and each of CRP (r=0.97) and LC (r=0.83).
  • CONCLUSION: This study shows remarkable cytotoxic/chemoenhancing effects for EGCG and introduces CRP as a predictor of both tumor's progression and responsiveness to chemotherapy.
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / pharmacology. Anti-Inflammatory Agents / therapeutic use. Antioxidants / pharmacology. Antioxidants / therapeutic use. C-Reactive Protein / metabolism. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Female. Glomerular Filtration Rate / drug effects. Kidney / drug effects. Kidney / physiopathology. Male. Malondialdehyde / blood. Mice. Phytotherapy. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Rats. Rats, Sprague-Dawley. Signal Transduction / drug effects

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20851589.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Cytokines; 0 / Plant Extracts; 0 / Renal Agents; 4Y8F71G49Q / Malondialdehyde; 8R1V1STN48 / Catechin; 9007-41-4 / C-Reactive Protein; BQM438CTEL / epigallocatechin gallate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Tang BH, Cui W, Wang JF, Yan MH, Li J: [Study on role of Chengqi Shengxue prescription in anti-tumor and immunoregulation]. Zhongguo Zhong Yao Za Zhi; 2008 Feb;33(3):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on role of Chengqi Shengxue prescription in anti-tumor and immunoregulation].
  • OBJECTIVE: To investigate the role of Chengqi Shengxue prescription in anti-tumor and immunoregulation and to evaluate its effect on apoptosis and T lymphocyte subsets of tumor-bearing mice.
  • METHOD: S180 ascites tumor and Lewis lung carcinoma tumor-bearing mice were used in the screening.
  • After the treatment apoptosis of tumor cell and peripheral T lymphocyte subsets of tumor-bearing mice was analyzed by flow cytometry.
  • RESULT: Lewis lung carcinoma was a nsitive tumor cell line to Chengqi Shengxue prescription.
  • CONCLUSION: Chengqi Shengxue prescription has selectively inhibitive effect on the growth of mouse Lewis lung carcinoma and takes an antitransfer role.
  • Its anti-tumor effect may be owing to inducing tumor cell apoptosis.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Lewis Lung / drug therapy. Male. Mice. Mice, Inbred C57BL

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536468.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


74. Zahran MA, Salem TA, Samaka RM, Agwa HS, Awad AR: Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. Bioorg Med Chem; 2008 Nov 15;16(22):9708-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice.
  • These compounds were screened for in vitro antitumor activity against Ehrlich ascites carcinoma (EAC) cell line and exhibited potent cytotoxic activity.
  • On the bases of the obtained results for in vitro cytotoxic activity, thalidomide sulfur analogs containing two sulfur atoms 8, 9, 13 and 14 were selected and tested in vivo against EAC-induced solid tumor in female mice compared to thalidomide 1 as well as its analog 2 and exhibited a highly significant reduction in tumor volume (TV).
  • The histopathological investigations revealed that thalidomide sulfur analogs 2, 8, 9, 13 and 14 have antimitotic, apoptotic and necrotic activities against solid tumor.
  • The immunohistochemical studies showed a decrease in Ki67 and vascular endothelial growth factor (VEGF) staining in tumor cells from treated-animals when compared with non-treated groups, which suggests an inhibition of tumor proliferation rate and angiogenic process associated with tumor growth.
  • Compounds 9 and 13 were the most potent compounds in tumor necrosis without liver necrosis.
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Animals. Antioxidants / chemistry. Antioxidants / pharmacology. Carcinoma, Ehrlich Tumor / metabolism. Carcinoma, Ehrlich Tumor / pathology. Catalase / metabolism. Cell Line, Tumor. Female. Lipid Peroxidation / drug effects. Mice. Superoxide Dismutase / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951804.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; EC 1.11.1.6 / Catalase; EC 1.15.1.- / superoxide dismutase 1; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


75. Shawali AS, Sherif SM, Darwish MA, El-merzabani MM: Synthesis and antitumor screening of new 1,7-diphenyl-3-(1,3-disubstituted-1H-pyrazole-4-carbonyl)-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones. Arch Pharm Res; 2010 Jan;33(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preliminary screening for antitumor activity of the synthesized compounds was carried out against Ehrlich Ascites Carcinoma tumor cells.
  • The results revealed that the studied compounds 4 have low or no antitumor activity towards EAC tumor cells.
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / pathology. Cell Line, Tumor. Doxorubicin / therapeutic use. Drug Screening Assays, Antitumor. Indicators and Reagents. Magnetic Resonance Spectroscopy. Mass Spectrometry. Mice. Spectrophotometry, Infrared

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191343.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Indicators and Reagents; 0 / Pyrimidinones; 0 / Triazoles; 80168379AG / Doxorubicin
  •  go-up   go-down


76. Thiry M, Ploton D: Isolation of nucleoli from Ehrlich ascites tumor cells and dynamics of nascent RNA within isolated nucleoli. Methods Mol Biol; 2008;463:111-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of nucleoli from Ehrlich ascites tumor cells and dynamics of nascent RNA within isolated nucleoli.
  • Here we describe a new, rapid method for isolating nucleoli from Ehrlich tumor cells that preserves their morphological integrity and high transcriptional activity.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / metabolism. Cell Nucleolus / metabolism. Cell Nucleus / metabolism. RNA / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951164.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA Precursors; 0 / RNA, Ribosomal; 63231-63-0 / RNA; UT0S826Z60 / Uridine Triphosphate
  •  go-up   go-down


77. Tanaka H, Kageyama K, Asada R, Yoshimura N, Miwa N: Promotive effects of hyperthermia on the cytostatic activity to Ehrlich ascites tumor cells by diverse delta-alkyllactones. Exp Oncol; 2008 Jun;30(2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promotive effects of hyperthermia on the cytostatic activity to Ehrlich ascites tumor cells by diverse delta-alkyllactones.
  • METHODS: A suspension of Ehrlich ascites tumor (EAT) cells was mixed with a DAL in a glass tube, heated at 37 or 42 degrees C for 30 min in a water bath, and cultured at 37 degrees C for 20 or 72 h.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / therapy. Hyperthermia, Induced. Lactones / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival. Models, Chemical. Oxidation-Reduction. Temperature

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18566579.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lactones
  •  go-up   go-down


78. El-Far M, Elmegeed GA, Eskander EF, Rady HM, Tantawy MA: Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents. Eur J Med Chem; 2009 Oct;44(10):3936-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study is to synthesize and evaluate new potential chemotherapeutic anti-tumor agents.
  • The most pure and structurally promising compounds 7a, 10a, 12b, 18 and 23 were evaluated as anti-tumor agents.
  • Also the in vivo anti-tumor activity was evaluated against Ehrlich ascites carcinoma (EAC).
  • Our novel steroid derivatives are promising candidates as anti-cancer agents, none of the mice treated with our novel derivatives showed any toxic symptoms, but they also completely inhibited tumor growth and retained the hemoglobin content, body weight, and WBCs near normal values and similar to what obtained for the standard drug 5-flurouracil.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Dihydrotestosterone / analogs & derivatives. Dihydrotestosterone / therapeutic use
  • [MeSH-minor] Animals. Body Weight / drug effects. Carcinoma, Hepatocellular / drug therapy. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Female. Hematologic Tests. Humans. Inhibitory Concentration 50. Liver Neoplasms / drug therapy. Mice. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447526.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 08J2K08A3Y / Dihydrotestosterone
  •  go-up   go-down


79. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Sawamura K, Tanaka K, Namai E, Oda Y, Matsumura Y, Maruyama K: Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Control Release; 2008 Jan 22;125(2):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles.
  • In this study, Bubble liposomes were compared with cationic lipid (CL)-DNA complexes as potential gene delivery carriers into tumor in vivo.
  • In addition, Bubble liposomes could introduce the luciferase gene more effectively than CL-DNA complexes into mouse ascites tumor cells and solid tumor tissue.
  • We conclude that the combination of Bubble liposomes and ultrasound is a minimally-invasive and tumor specific gene transfer method in vivo.
  • [MeSH-minor] Animals. COS Cells. Cell Line, Tumor. Cercopithecus aethiops. Erythrocytes / drug effects. Gene Targeting / methods. Hemolysis / drug effects. Male. Mice

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. Octafluoropropane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035442.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Liposomes; 9007-49-2 / DNA; CK0N3WH0SR / perflutren
  •  go-up   go-down


80. Nersesyan A, Muradyan R, Arsenyan F: The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth. J BUON; 2007 Oct-Dec;12(4):521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth.
  • MATERIALS AND METHODS: The compounds were tested for their toxicity and MN-inducing activities in HeLa tumor cell line and Swiss mice.
  • Antitumor activity was studied on mouse Ehrlich ascites carcinoma (EAC) by means of evaluation of tumor (ascites) volume and mean lifespan (MLS).
  • One day after the last injection half of the mice with EAC were sacrificed and antitumor activity was assessed by means of ascites volume inhibition.
  • Also the frequency of MN and the number of viable cells (by means of trypan blue exclusion) was evaluated in ascites.
  • Antitumor effect of combined action of the compounds with CP (based on the ascites volume) was increased compared with CP effect by 17.7% (p >0.05; DGS-658 and DGS-664A) and 28.2% (p <0.001; DGS- 666).
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor / pathology. Cell Proliferation / drug effects. HeLa Cells. Heterocyclic Compounds, 2-Ring. Humans. Mice. Micronuclei, Chromosome-Defective / chemically induced. Micronucleus Tests

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067211.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DGS-658; 0 / DGS-664A; 0 / DGS-666; 0 / Heterocyclic Compounds, 2-Ring; 0 / Pyrazoles; 0 / Pyrimidines; K8CXK5Q32L / pyrimidine
  •  go-up   go-down


81. Hazra B, Das Sarma M, Kumar B, Basu S, Das K, Pandey BN, Mishra KP: Cytotoxicity of diospyrin and its derivatives in relation to the generation of reactive oxygen species in tumour cells in vitro and in vivo. Chemotherapy; 2007;53(3):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of diospyrin and its derivatives in relation to the generation of reactive oxygen species in tumour cells in vitro and in vivo.
  • BACKGROUND: Alkyl ethers (D2 and D7) synthesized from diospyrin (D1), a naphthoquinonoid isolated from Diospyros montana Roxb., were evaluated for cytotoxicity and capacity to generate reactive oxygen species (ROS) in tumour cells.
  • METHODS: The tumour inhibitory activity of the quinonoids was assessed in vivo against Ehrlich ascites carcinoma (EAC), while cytotoxicity was determined in vitro on EAC and MCF-7 cancer cells by MTT assay.
  • RESULTS: The tumour inhibitory activity, cytotoxicity and ROS generation capacity of quinonoids were found to be D7 > D2 > D1.
  • CONCLUSION: Alkyl ethers of D1 were more cytotoxic against tumour cells in vitro as well as in vivo.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Ethers / pharmacology. Naphthoquinones / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Lipid Peroxidation. Mice. Reactive Oxygen Species / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17347562.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Ethers; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 28164-57-0 / diospyrin
  •  go-up   go-down


82. Kumar A, D'Souza SS, Tickoo S, Salimath BP, Singh HB: Antiangiogenic and proapoptotic activities of allyl isothiocyanate inhibit ascites tumor growth in vivo. Integr Cancer Ther; 2009 Mar;8(1):75-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic and proapoptotic activities of allyl isothiocyanate inhibit ascites tumor growth in vivo.
  • The authors investigate the antiangiogenic and proapoptotic effects of mustard essential oil containing allyl isothiocyanate (AITC) and explore its mechanism of action on Ehrlich ascites tumor (EAT) cells.
  • It significantly reduced ascites secretion and tumor cell proliferation by about 80% and inhibited vascular endothelial growth factor expression in tumor-bearing mice in vivo.
  • The results clearly suggest that AITC inhibits tumor growth by both antiangiogenic and proapoptotic mechanisms.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Isothiocyanates / pharmacology. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. G1 Phase / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Mustard Plant / chemistry. Neoplasm Transplantation. Plant Oils / chemistry. Rabbits. Rats. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALLYL ISOTHIOCYANATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223371.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Isothiocyanates; 0 / Plant Oils; 0 / Vascular Endothelial Growth Factor A; BN34FX42G3 / allyl isothiocyanate
  •  go-up   go-down


83. Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP: Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine; 2007 Dec;3(4):246-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissue distribution studies were performed with DOX-loaded HA-PEG-PLGA and MPEG-PLGA nanoparticles after intravenous (IV) injection in Ehrlich ascites tumor-bearing mice.
  • The tissue distribution studies showed a higher concentration of DOX in the tumor as compared with MPEG-PLGA nanoparticles.
  • The in vivo tumor inhibition study was also performed after IV injection of DOX-loaded HA-PEG-PLGA nanoparticles up to 15 days.
  • The DOX-loaded HA-PEG-PLGA nanoparticles reduced tumor volume significantly as compared with MPEG-PLGA nanoparticles.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Drug Carriers / chemistry. Hyaluronic Acid / chemistry. Lactic Acid / chemistry. Nanoparticles / chemistry. Polyglycolic Acid / chemistry. Polymers / chemistry

  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068091.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Immunoglobulin G; 0 / Polymers; 0 / antineoplastic agent K 18; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; 80168379AG / Doxorubicin; 9004-61-9 / Hyaluronic Acid; Q41OR9510P / Melphalan
  •  go-up   go-down


84. Meerovich IG, Smirnova ZS, Oborotova NA, Luk'yanets EA, Meerovich GA, Derkacheva VM, Polozkova AP, Kubasova IY, Baryshnikov AY: Hydroxyaluminium tetra-3-phenylthiophthalocyanine is a new effective photosensitizer for photodynamic therapy and fluorescent diagnosis. Bull Exp Biol Med; 2005 Apr;139(4):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments on mice with solid Ehrlich tumor and subcutaneously transplanted P-388 leukemia revealed high selectivity of accumulation of the photosensitizer in tumors in comparison with normal tissues and high photodynamic activity of the preparation.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Indoles / therapeutic use. Leukemia P388 / drug therapy. Organometallic Compounds / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027872.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Organometallic Compounds; 0 / Photosensitizing Agents; 0 / hydroxyaluminum tetra-3-phenylthiophthalocyanine
  •  go-up   go-down


85. Prabhakar BT, Khanum SA, Jayashree K, Salimath BP, Shashikanth S: Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. Bioorg Med Chem; 2006 Jan 15;14(2):435-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells.
  • In the present report, we investigated the anti-tumor and proapoptotic effect of benzophenones in Ehrlich ascites tumor (EAT) cells.
  • Treatment of benzophenones in vivo resulted in inhibition of proliferation of EAT cells and ascites formation.
  • These results suggest a further possible clinical application of these synthetic compounds as potent anti-tumor and proapoptotic compounds.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Benzophenones / pharmacology. Carcinoma, Ehrlich Tumor / pathology
  • [MeSH-minor] Animals. Caspase 3. Caspase Inhibitors. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. DNA, Neoplasm / drug effects. Female. Magnetic Resonance Spectroscopy. Mice. Phosphatidylserines / metabolism. Spectrometry, Mass, Electrospray Ionization. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214348.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzophenones; 0 / Caspase Inhibitors; 0 / DNA, Neoplasm; 0 / Phosphatidylserines; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


86. Mandal D, Lahiry L, Bhattacharyya A, Chattopadhyay S, Siddiqi M, Sa G, Das T: Black tea protects thymocytes in tumor-bearing animals by differential regulation of intracellular ROS in tumor cells and thymocytes. J Environ Pathol Toxicol Oncol; 2005;24(2):91-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Black tea protects thymocytes in tumor-bearing animals by differential regulation of intracellular ROS in tumor cells and thymocytes.
  • The accumulated in vitro evidence indicates that many tumors induce T-cell apoptosis as a mechanism of inhibiting antitumor activity.
  • This downregulation of cell-mediated immune functions occurring at the late stages of the disease may be causally related to the thymic involution, because the thymus is the major site of T-cell maturation, extensive proliferation, and differentiation.
  • Our results showed that in Erhlich's ascites carcinoma cell (EAC)-bearing mice, the number of EAC was inversely proportional to the thymocyte count in the host's thymus, which is the primary immune organ.
  • Further studies indicated the presence of tumor-induced thymocyte apoptosis in EAC bearers.
  • Black tea prolonged the survival of the tumor bearer by successfully restricting tumor progression as well as protecting the thymus from tumor insult.
  • As a result, the maturation block in thymocyte subpopulations in tumor bearers was ameliorated significantly in black tea-treated animals.
  • Our results demonstrate that black tea protects thymocytes in the tumor bearer by regulating the intracellular ROS in tumor cells and thymocytes differentially, thereby strengthening its candidacy in future anticancer therapeutic regimens.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Antioxidants / pharmacology. Carcinoma, Ehrlich Tumor / metabolism. Reactive Oxygen Species / metabolism. T-Lymphocytes / drug effects. Tea
  • [MeSH-minor] Animals. Apoptosis / drug effects. Camellia sinensis. Cell Count. Cell Cycle. Cell Line, Tumor. Cell Survival. Mice. Neoplasm Transplantation. Plant Extracts / pharmacology. Ploidies. T-Lymphocyte Subsets / drug effects. Thymus Gland / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15831082.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / Tea
  •  go-up   go-down


87. Segura JA, Donadio AC, Lobo C, Matés JM, Márquez J, Alonso FJ: Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells. Cancer Lett; 2005 Jan 31;218(1):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells.
  • Tumor cells expressing antisense glutaminase RNA show a drastic inhibition of glutaminase activity and they acquire a more differentiated phenotype.
  • We have studied the expression of Sp1 and Sp3 transcription factors in both Ehrlich tumor cells and their derivative 0.28AS-2 antisense glutaminase expressing cells.
  • Incubation of Ehrlich tumor cells with the differentiation agent PMA could not totally reproduce the Sp1/Sp3 changes observed in 0.28AS-2 cells.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / genetics. Carcinoma, Ehrlich Tumor / pathology. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / metabolism. Glutaminase / biosynthesis. Sp1 Transcription Factor / biosynthesis. Sp1 Transcription Factor / metabolism. Transcription Factors / biosynthesis. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15639344.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Antisense; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; 148710-94-5 / Sp3 Transcription Factor; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


88. Kwiecień I, Michalska M, Włodek L: The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice. Eur J Pharmacol; 2006 Nov 21;550(1-3):39-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice.
  • The aim of the present study was to examine the protective effect of cystathionine as a cysteine precursor on doxorubicin toxicity in the liver of Ehrlich ascites tumor (EAT)-bearing mice and in the EAT cells.
  • All these data indicate that cystathionine action is selectively beneficial for normal cells because it corrects harmful effects induced by EAT development and protects the organism against doxorubicin cytotoxicity without impairing cytotoxicity of this drug to tumor cells.
  • [MeSH-major] Antibiotics, Antineoplastic / antagonists & inhibitors. Antibiotics, Antineoplastic / toxicity. Carcinoma, Ehrlich Tumor / pathology. Cystathionine / pharmacology. Doxorubicin / antagonists & inhibitors. Doxorubicin / toxicity. Drug-Induced Liver Injury / prevention & control

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034787.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Indicators and Reagents; 0 / Reactive Oxygen Species; 375YFJ481O / Cystathionine; 4Y8F71G49Q / Malondialdehyde; 80168379AG / Doxorubicin; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.5.1.18 / Glutathione Transferase; EC 3.1.3.1 / Alkaline Phosphatase; EC 4.4.1.1 / Cystathionine gamma-Lyase; GAN16C9B8O / Glutathione
  •  go-up   go-down


89. Haldar PK, Kar B, Bala A, Bhattacharya S, Mazumder UK: Antitumor activity of Sansevieria roxburghiana rhizome against Ehrlich ascites carcinoma in mice. Pharm Biol; 2010 Dec;48(12):1337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of Sansevieria roxburghiana rhizome against Ehrlich ascites carcinoma in mice.
  • OBJECTIVE: To evaluate the hydroalcoholic extract of S. roxburghiana rhizome (HASR) for antitumor activity against Ehrlich ascites carcinoma (EAC) in Swiss albino mice.
  • METHODS: Twenty-Four hours after intraperitoneal inoculation of tumor (EAC) cells in mice, HASR was administered at 50 and 100 mg/kg body weight for nine consecutive days.
  • The antitumor effect of HASR was assessed by evaluating tumor volume, packed cell count, viable and non-viable tumor cell count, median survival time and increase in life-span of EAC bearing hosts.
  • RESULTS AND DISCUSSION: HASR showed a significant (p < 0.001) decrease in tumor volume, packed cell volume and viable cell count and increased the life span of EAC bearing mice.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Plant Extracts / pharmacology. Sansevieria / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091122.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Plant Extracts; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione
  •  go-up   go-down


90. Martín-Rufián M, Segura JA, Lobo C, Matés JM, Márquez J, Alonso FJ: Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. Cancer Biol Ther; 2006 Jan;5(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display.
  • Ehrlich ascites tumor cells (EATC) is a highly proliferative malignant cell line derived from mouse mammary epithelia, whereas their derivative, 0.28AS-2 cells, expressing antisense glutaminase mRNA, show a less transformed phenotype and loss of their tumorigenic capacity in vivo correlated with an inhibition of glutaminase expression.
  • Our results show the validity of mRNA differential display technique to get insights into the molecular mechanisms underlying the acquisition of a more differentiated phenotype by tumor cells after inhibition of glutaminase expression.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / enzymology. Carcinoma, Ehrlich Tumor / genetics. Gene Expression Regulation, Neoplastic. Glutaminase / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. DNA, Complementary / genetics. Down-Regulation. Gene Expression Regulation, Enzymologic. Mice. RNA, Antisense / genetics. RNA, Antisense / metabolism. RNA, Messenger / analysis. Rats

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294018.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Antisense; 0 / RNA, Messenger; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


91. Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK: Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm; 2008 Aug;34(8):789-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
  • The DOX prodrug N-(beta-D-glucopyranosylbenzyloxycarbonyl)-doxorubicin (prodrug 1) was synthesized for specific activation by beta-galactosidase, which is expected to release in necrotic areas of tumor lesions.
  • In vivo safety evaluation was done in the Ehrlich Ascites Carcinoma (EAC) tumor model.
  • [MeSH-minor] Animals. Area Under Curve. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Female. Half-Life. Metabolic Clearance Rate. Mice. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608462.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Galactosides; 0 / Prodrugs; 0 / beta-galactoside; 80168379AG / Doxorubicin
  •  go-up   go-down


92. Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM: Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun; 2008 Jan;22(1):65-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Less is known about the relationship between psychosocial factors and NKT cells, a rare group of lymphocytes that have known relevance for tumor control.
  • We examined four psychosocial factors and percentage and number of CD3+CD56+ NKT cells, CD3-CD56+ NK cells, and CD3+CD56- T cells in peripheral blood lymphocytes (PBL), ascites, and tumor of 35 ovarian cancer patients and 28 patients with benign pelvic masses.
  • Ascites and tumor were taken during surgery.
  • Among cancer patients, NKT cell percentage was significantly higher in tumor and ascites than in PBL; T cell percentage was significantly higher in PBL than tumor.
  • NKT, NK, and T cell number were significantly higher in peripheral blood than in ascites.
  • Social support was related to significantly higher NKT cell percentage in tumor.
  • Given the anti-tumor activity of CD3+CD56+ cells, these relationships may have relevance for cancer control.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Abnorm Psychol. 1984 Nov;93(4):378-90 [6512084.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):153-64 [15664788.001]
  • [Cites] Brain Behav Immun. 2005 May;19(3):185-94 [15797305.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Cancer Immunol Immunother. 2005 Dec;54(12):1162-71 [15889254.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jun;55(6):734-43 [16283306.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S27-36 [12615183.001]
  • [Cites] J Neuroimmunol. 2003 May;138(1-2):17-24 [12742648.001]
  • [Cites] Psychosom Med. 2003 Jul-Aug;65(4):571-81 [12883107.001]
  • [Cites] World J Gastroenterol. 2004 Jan 15;10(2):268-72 [14716837.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):106-15 [14975591.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):231-7 [15039760.001]
  • [Cites] Psychiatry Res. 2004 Jul 15;127(3):237-45 [15296823.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):911-24 [15127235.001]
  • [Cites] J Neuroimmunol. 2004 Nov;156(1-2):153-62 [15465606.001]
  • [Cites] Hum Immunol. 2000 Jan;61(1):44-50 [10658977.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] J Invest Dermatol. 2000 May;114(5):941-7 [10771475.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):515-20 [11101874.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):521-5 [11101875.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):131-40 [11815969.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):745-51 [11895904.001]
  • [Cites] J Pers Soc Psychol. 1984 Jun;46(6):1313-21 [6737214.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4480-6 [3086432.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):351-6 [3088199.001]
  • [Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]
  • [Cites] Psychosom Med. 1990 Jan-Feb;52(1):73-85 [2305024.001]
  • [Cites] Behav Med. 1990 Fall;16(3):101-10 [2224168.001]
  • [Cites] Soc Sci Med. 1991;33(2):177-83 [1887281.001]
  • [Cites] Fukuoka Igaku Zasshi. 1991 Oct;82(10):499-507 [1748365.001]
  • [Cites] Circulation. 1994 Feb;89(2):762-9 [7508828.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 Mar;1(2):125-33 [7496932.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):631-7 [8625157.001]
  • [Cites] Brain Behav Immun. 1996 Jun;10(2):77-91 [8811932.001]
  • [Cites] J Psychosom Res. 1997 May;42(5):453-66 [9194018.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5239-45 [9605119.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • [Cites] J Pers Assess. 1983 Jun;47(3):305-6 [6886962.001]
  • [Cites] Cancer Immunol Immunother. 2002 Oct;51(8):440-8 [12202905.001]
  • (PMID = 17643954.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R01 CA104825-05; United States / NCI NIH HHS / CA / R21 CA088293-01; United States / NCI NIH HHS / CA / CA088293-01; United States / NCI NIH HHS / CA / R21 CA088293; United States / NCI NIH HHS / CA / CA104825-05
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56
  • [Other-IDs] NLM/ NIHMS232786; NLM/ PMC2964139
  •  go-up   go-down


93. Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, Singh N: Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis. Cancer Chemother Pharmacol; 2005 Oct;56(4):427-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression.
  • The objective of this study was to compare the expression levels of both proapoptotic and antiapoptotic proteins p53, p73, Bcl-2, Bcl-XL and survivin in the ascitic cells and tumor samples of patients undergoing treatment with two different regimens.
  • The expression of apoptosis-related proteins was analyzed in ascitic fluid and tumor samples by Western blotting and immunohistochemistry.
  • RESULTS: Significant decreases in antiapoptotic bcl-2 and survivin were seen, accompanied by increases in apoptotic index in tumors that had undergone chemotherapy as compared to the baseline ascites samples.
  • No expression of p73 was observed in tumors or ascites.
  • CONCLUSIONS: The above findings indicate that chemotherapy in ovarian carcinoma leads to an increase in apoptosis by a p53-independent pathway, which involves the downregulation of antiapoptotic Bcl-2 and survivin but not Bcl-XL.


94. Silva LA, Nascimento KA, Maciel MC, Pinheiro MT, Sousa PR, Ferreira SC, Azevedo AP, Guerra RN, Nascimento FR: Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice. Chemotherapy; 2006;52(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice.
  • BACKGROUND: Sunflower seed oil (SSO) effect on solid and ascitic forms of Ehrlich tumor was evaluated.
  • METHODS: Solid or ascitic Ehrlich tumor-bearing Swiss mice were treated daily, by subcutaneous route, with 200 microl of SSO.
  • The solid tumor-bearing footpad was measured every 3 days and ascitic tumor-bearing mice had their ascites collected and quantified.
  • RESULTS: Subcutaneous treatment with SSO inhibits the solid tumor growth and increases lymph node cell number in animals with solid tumor, but has no effect on animals with ascitic tumor.
  • CONCLUSIONS: SSO can delay the solid tumor growth, possibly due to better absorption of this treatment by draining lymph nodes.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Plant Oils / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16462141.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Oils; 8001-21-6 / sunflower seed oil
  •  go-up   go-down


95. Novikov VV, Novikov GV, Fesenko EE: Effect of weak combined static and extremely low-frequency alternating magnetic fields on tumor growth in mice inoculated with the Ehrlich ascites carcinoma. Bioelectromagnetics; 2009 Jul;30(5):343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of weak combined static and extremely low-frequency alternating magnetic fields on tumor growth in mice inoculated with the Ehrlich ascites carcinoma.
  • The parameters of this component have been found (frequency 1, 4.4, 16.5 Hz or the sum of these frequencies; intensity 300, 100, 150-300 nT, respectively) at which this MF in combination with a collinear static MF of 42 microT inhibits or suppresses the growth of Ehrlich ascites carcinoma (EAC) in mice.
  • It was shown that the exposure of mice with EAC to combined MFs causes structural changes in some organs (liver, adrenal glands), which are probably due to the total degradation of the tumor tissue.
  • In mice with transplanted EAC, the tumor tissue after exposure to weak MFs was practically absent, as distinct from control animals in which the invasion of the tumor into the adipose tissue surrounding the kidneys, mesenteric lymph nodes, and spermatic appendages was observed.
  • In animals without tumors, no pathological deviations from the norm in the structure of organs and tissues occurred after exposure to weak MF, indicating that this factor per se is not toxic to the organism.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / pathology. Carcinoma, Ehrlich Tumor / therapy. Magnetic Field Therapy / methods. Magnetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19267367.001).
  • [ISSN] 1521-186X
  • [Journal-full-title] Bioelectromagnetics
  • [ISO-abbreviation] Bioelectromagnetics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Stachtea X, Karamanos N, Klouras N: Enhanced antitumour activity of cyclopendadienyl-substituted metallocene dihalides in human breast and colon cancer cells. Anticancer Res; 2009 Aug;29(8):3227-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ; M=Ti, Zr, Hf, V or Nb; and X=halogen), are highly effective agents against Ehrlich ascites tumour cells and lymphocytic leukaemia.
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Humans. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661339.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / metallocene
  •  go-up   go-down


97. Unahara Y, Kojima-Yuasa A, Higashida M, Kennedy DO, Murakami A, Ohigashi H, Matsui-Yuasa I: Cellular thiol status-dependent inhibition of tumor cell growth via modulation of p27(kip1) translocation and retinoblastoma protein phosphorylation by 1'-acetoxychavicol acetate. Amino Acids; 2007 Sep;33(3):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular thiol status-dependent inhibition of tumor cell growth via modulation of p27(kip1) translocation and retinoblastoma protein phosphorylation by 1'-acetoxychavicol acetate.
  • 1'-Acetoxychavicol acetate (ACA) has been shown to inhibit tumor cell growth, but there is limited information on its effects on cell signaling and the cell cycle control pathway.
  • In this study, we sought to determine how ACA alters cell cycle and its related control factors in its growth inhibitory effect in Ehrlich ascites tumor cells (EATC).
  • [MeSH-minor] Acetylcysteine / metabolism. Animals. Benzyl Alcohols. Carcinoma, Ehrlich Tumor. Cell Line, Tumor. DNA / biosynthesis. Glutathione / analogs & derivatives. Glutathione / metabolism. Humans. Phosphorylation. Plant Extracts / chemistry. Plant Extracts / metabolism

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031475.001).
  • [ISSN] 1438-2199
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Benzyl Alcohols; 0 / Plant Extracts; 0 / Retinoblastoma Protein; 0 / Sulfhydryl Compounds; 0 / Terpenes; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 24425-52-3 / S-ethyl glutathione; 52946-22-2 / 1'-acetoxychavicol acetate; 9007-49-2 / DNA; GAN16C9B8O / Glutathione; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


98. Kirkegaard SS, Lambert IH, Gammeltoft S, Hoffmann EK: Activation of the TASK-2 channel after cell swelling is dependent on tyrosine phosphorylation. Am J Physiol Cell Physiol; 2010 Oct;299(4):C844-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The swelling-activated K(+) currents (I(K,vol)) in Ehrlich ascites tumor cells (EATC) has been reported to be through the two-pore domain (K(2p)), TWIK-related acid-sensitive K(+) channel 2 (TASK-2).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631251.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hypotonic Solutions; 0 / KCNK5 protein, human; 0 / Potassium Channels, Tandem Pore Domain; 0 / STAT Transcription Factors; 42HK56048U / Tyrosine; DH2M523P0H / Genistein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinases; RWP5GA015D / Potassium
  •  go-up   go-down


99. Gol'dberg ED, Amosova EN, Zueva EP, Razina TG, Krylova SG, Zorikov PS: Licorice preparations improve efficiency of chemotherapy and surgical treatment of transplanted tumors. Bull Exp Biol Med; 2008 Feb;145(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Licorice preparations improve efficiency of chemotherapy and surgical treatment of transplanted tumors.
  • Experiments on animals with Lewis lung carcinoma and Ehrlich tumor showed that licorice (glycyrrhiza) extract and glyciram prepared from this plant improved the antitumor effect of cyclophosphamide.
  • Licorice extract inhibited the growth of Ehrlich tumor and development of metastases in mice with Lewis lung carcinoma.
  • Glyciram administered to mice after removal of Lewis lung carcinoma produced an antimetastatic effect and prevented relapses.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / surgery. Carcinoma, Lewis Lung / drug therapy. Carcinoma, Lewis Lung / surgery. Glycyrrhiza / chemistry. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023982.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts; P540XA09DR / Glycyrrhetinic Acid
  •  go-up   go-down


100. Valadares MC, de Carvalho IC, de Oliveira Junior L, Vieira Mde S, Benfica PL, de Carvalho FS, Andrade LV, Lima EM, Kato MJ: Cytotoxicity and antiangiogenic activity of grandisin. J Pharm Pharmacol; 2009 Dec;61(12):1709-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The antitumoural properties of grandisin, a tetrahydrofuran neolignan from Piper solmsianum, were investigated by in-vitro and in-vivo assays using the Ehrlich ascites tumoural (EAT) model.
  • METHODS: Viability of the tumour cells was evaluated by Trypan blue exclusion and MTT methods, after incubation with grandisin (0.017-2.3 microm).
  • Simultaneously, we detected a 66.35% reduction of intraperitoneal tumour cell burden in the animals treated with 10 mg/kg grandisin.
  • CONCLUSIONS: The results demonstrated that grandisin induced in-vitro cytotoxicity and antiangiogenic effects in mice while it acted against tumour evolution, prolonging host survival.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Cell Proliferation / drug effects. Furans / therapeutic use. Lignans / therapeutic use. Piper / chemistry. Plant Extracts / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958595.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Phytogenic; 0 / Furans; 0 / Lignans; 0 / Plant Extracts; 0 / Vascular Endothelial Growth Factor A; 53250-50-3 / grandisin; EC 3.4.22.- / Caspases
  •  go-up   go-down






Advertisement